<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Proc Natl Acad Sci U S A</journal-id><journal-id journal-id-type="iso-abbrev">Proc Natl Acad Sci U S A</journal-id><journal-id journal-id-type="hwp">pnas</journal-id><journal-id journal-id-type="publisher-id">PNAS</journal-id><journal-title-group><journal-title>Proceedings of the National Academy of Sciences of the United States of America</journal-title></journal-title-group><issn pub-type="ppub">0027-8424</issn><issn pub-type="epub">1091-6490</issn><publisher><publisher-name>National Academy of Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">35239443</article-id><article-id pub-id-type="pmc">PMC8915830</article-id><article-id pub-id-type="publisher-id">202112397</article-id><article-id pub-id-type="doi">10.1073/pnas.2112397119</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>425</subject></subj-group><subj-group subj-group-type="heading"><subject>Biological Sciences</subject><subj-group><subject>Pharmacology</subject></subj-group></subj-group></article-categories><title-group><article-title>Discovery of a functionally selective ghrelin receptor (GHSR<sub>1a</sub>) ligand for modulating brain dopamine</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0925-6331</contrib-id><name><surname>Gross</surname><given-names>J. D.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>D. W.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Y.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jansen</surname><given-names>D.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9471-9117</contrib-id><name><surname>Slosky</surname><given-names>L. M.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Clark</surname><given-names>N. B.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ray</surname><given-names>C. R.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>X.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4500-880X</contrib-id><name><surname>Southall</surname><given-names>N.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>A.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>X.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Barnaeva</surname><given-names>E.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3592-7397</contrib-id><name><surname>Wetsel</surname><given-names>W. C.</given-names></name><xref rid="aff3" ref-type="aff">
<sup>c</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ferrer</surname><given-names>M.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3951-7061</contrib-id><name><surname>Marugan</surname><given-names>J. J.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>b</sup>
</xref><xref rid="cor1" ref-type="corresp">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Caron</surname><given-names>M. G.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="cor1" ref-type="corresp">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9170-2141</contrib-id><name><surname>Barak</surname><given-names>L. S.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="cor1" ref-type="corresp">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6590-6394</contrib-id><name><surname>Toth</surname><given-names>K.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>a</sup>
</xref><xref rid="fn5" ref-type="author-notes">
<sup>2</sup>
</xref></contrib><aff id="aff1"><sup>a</sup>Department of Cell Biology, <institution>Duke University Medical Center</institution>, Durham, NC 27710;</aff><aff id="aff2"><sup>b</sup>National Center for Advancing Translational Sciences, <institution>NIH Division of Preclinical Innovation</institution>, Rockville, MD 20892;</aff><aff id="aff3"><sup>c</sup>Department of Psychiatry and Behavioral Sciences, <institution>Duke University Medical Center</institution>, Durham, NC 27710;</aff><aff id="aff4"><sup>d</sup>Mouse Behavioral and Neuroendocrine Analysis Core Facility, <institution>Duke University Medical Center</institution>, Durham, NC 27710</aff></contrib-group><author-notes><corresp id="cor1"><sup>1</sup>To whom correspondence may be addressed. Email: <email>maruganj@mail.nih.gov</email>, <email>marc.caron@duke.edu</email>, or <email>lawrence.barak@duke.edu</email>.</corresp><fn id="fn1" fn-type="edited-by"><p>Edited by Brian Kobilka, Stanford University School of Medicine, Stanford, CA; received July 6, 2021; accepted January 26, 2022</p></fn><fn id="fn2" fn-type="con"><p>Author contributions: J.D.G., D.W.K., Y.Z., D.J., W.C.W., M.F., J.J.M., M.G.C., L.S.B., and K.T. designed research; J.D.G., D.W.K., Y.Z., D.J., N.B.C., X.H., A.W., X.X., E.B., and K.T. performed research; D.W.K., D.J., and C.R.R. contributed new reagents/analytic tools; J.D.G., D.W.K., Y.Z., D.J., L.M.S., N.B.C., N.S., W.C.W., M.F., J.J.M., M.G.C., L.S.B., and K.T. analyzed data; and J.D.G., W.C.W., J.J.M., M.G.C., L.S.B., and K.T. wrote the paper.</p></fn><fn id="fn5" fn-type="present-address"><p><sup>2</sup>Present address:&#x000a0;Pharmaceutical Sciences, Campbell University, Buies Creek, NC 27506.</p></fn></author-notes><pub-date pub-type="epub"><day>3</day><month>3</month><year>2022</year></pub-date><pub-date pub-type="ppub"><day>8</day><month>3</month><year>2022</year></pub-date><pub-date pub-type="pmc-release"><day>3</day><month>3</month><year>2022</year></pub-date><volume>119</volume><issue>10</issue><elocation-id>e2112397119</elocation-id><history><date date-type="accepted"><day>26</day><month>1</month><year>2022</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2022 the Author(s). Published by PNAS.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This article is distributed under <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pnas.202112397.pdf"/><abstract abstract-type="executive-summary"><title>Significance</title><p>The modulation of growth hormone secretagogue receptor-1a (GHSR<sub>1a</sub>) signaling is a promising strategy for treating brain conditions of metabolism, aging, and addiction. GHSR<sub>1a</sub> activation results in pleiotropic physiological outcomes through distinct and pharmacologically separable G protein&#x02013; and &#x003b2;-arrestin (&#x003b2;arr)&#x02013;dependent signaling pathways. Thus, pathway-selective modulation can enable improved pharmacotherapeutics that can promote therapeutic efficacy while mitigating side effects. Here, we describe the discovery of a brain-penetrant small molecule, N8279 (NCATS-SM8864), that biases GHSR<sub>1a</sub> conformations toward G&#x003b1;<sub>q</sub> activation and reduces aberrant dopaminergic behavior in mice. N8279 represents a promising chemical scaffold to advance the development of better treatments for GHSR<sub>1a</sub>-related brain disorders involving the pathological dysregulation of dopamine.</p></abstract><abstract><p>The growth hormone secretagogue receptor-1a (GHSR<sub>1a</sub>) is the cognate G protein&#x02013;coupled receptor (GPCR) for the peptide hormone ghrelin. GHSR<sub>1a</sub> is a promising therapeutic target for a wide range of metabolic, age-related, and central nervous system (CNS)&#x02013;based conditions. In addition, growing evidence supports that GHSR<sub>1a</sub> is a modulator of dopamine (DA) homeostasis and is neuroprotective within brain DA circuits. GHSR<sub>1a</sub> signaling originates from pharmacologically separable G protein&#x02013; and &#x003b2;-arrestin (&#x003b2;arr)&#x02013;dependent pathways, and consequently, GHSR<sub>1a</sub>-mediated physiological responses depend upon their distinctive signaling contributions. Thus, when treating disorders of disrupted DA homeostasis, a pharmacological strategy that modulates biased GHSR<sub>1a</sub> signaling may uncouple desired therapeutic outcomes from unwanted side effects. Here, we report the discovery of a small molecule GHSR<sub>1a</sub> agonist, N8279 (NCATS-SM8864), functionally selective for G protein signaling. Comprehensive pharmacological characterization reveals that N8279 elicits potent G&#x003b1;<sub>q</sub> activity at the apo- and ghrelin-bound GHSR<sub>1a</sub>. Further biochemical analysis and molecular modeling demonstrate that N8279 signaling requires the extracellular domain of GHSR<sub>1a</sub>, especially extracellular loop 2. Collectively, these findings suggest that N8279 possesses an extended binding mode into the extracellular vestibule of the GHSR<sub>1a</sub> that preferentially favors G&#x003b1;<sub>q</sub> signaling over alternative G proteins and &#x003b2;arr2-dependent cellular responses. Critically, N8279 is brain-penetrant in mice, exhibits CNS stability, and attenuates dysfunctional DA-mediated behaviors in both genetic and pharmacological mouse models of hyperdopaminergia. Our findings provide insight into the mechanisms governing GPCR functional selectivity and emphasize how biased ligand drug development can produce novel GHSR<sub>1a</sub> pharmacotherapeutics to treat pathological disruptions of brain DA homeostasis.</p></abstract><kwd-group><kwd>NCATS-SM8864</kwd><kwd>functional selectivity</kwd><kwd>GPCR</kwd><kwd>ghrelin</kwd><kwd>dopamine</kwd></kwd-group><funding-group><award-group id="gs1"><funding-source id="sp1">HHS | NIH | National Institute on Drug Abuse (NIDA)<named-content content-type="funder-id">100000026</named-content></funding-source><award-id rid="sp1">F32DA051139</award-id><principal-award-recipient>Joshua Gross</principal-award-recipient><principal-award-recipient>Marc G Caron</principal-award-recipient><principal-award-recipient>Larry S. Barak</principal-award-recipient><principal-award-recipient>Krisztian Toth</principal-award-recipient></award-group><award-group id="gs2"><funding-source id="sp2">HHS | NIH | National Institute on Drug Abuse (NIDA)<named-content content-type="funder-id">100000026</named-content></funding-source><award-id rid="sp2">U18DA052417</award-id><principal-award-recipient>Joshua Gross</principal-award-recipient><principal-award-recipient>Marc G Caron</principal-award-recipient><principal-award-recipient>Larry S. Barak</principal-award-recipient><principal-award-recipient>Krisztian Toth</principal-award-recipient></award-group><award-group id="gs3"><funding-source id="sp3">HHS | NIH | National Institute on Drug Abuse (NIDA)<named-content content-type="funder-id">100000026</named-content></funding-source><award-id rid="sp3">P30DA029925</award-id><principal-award-recipient>Joshua Gross</principal-award-recipient><principal-award-recipient>Marc G Caron</principal-award-recipient><principal-award-recipient>Larry S. Barak</principal-award-recipient><principal-award-recipient>Krisztian Toth</principal-award-recipient></award-group><award-group id="gs4"><funding-source id="sp4">HHS | NIH | National Institute of Mental Health (NIMH)<named-content content-type="funder-id">100000025</named-content></funding-source><award-id rid="sp4">R37MH073853</award-id><principal-award-recipient>Marc G Caron</principal-award-recipient></award-group><award-group id="gs5"><funding-source id="sp5">HHS | NIH | National Center for Advancing Translational Sciences (NCATS)<named-content content-type="funder-id">100006108</named-content></funding-source><award-id rid="sp5">ZIATR000083</award-id><principal-award-recipient>Juan Marugan</principal-award-recipient></award-group></funding-group><counts><page-count count="12"/></counts></article-meta></front><body><p content-type="flushleft">Ghrelin is a peptide hormone secreted from gastric cells during energy deprivation to mediate food-seeking behavior and restore physiological homeostasis (<xref rid="r1" ref-type="bibr">1</xref>, <xref rid="r2" ref-type="bibr">2</xref>). Ghrelin exerts its effects via activation of the growth hormone secretagogue receptor-1a (GHSR<sub>1a</sub>), a G protein&#x02013;coupled receptor (GPCR) (<xref rid="r3" ref-type="bibr">3</xref>). In the brain, the GHSR<sub>1a</sub> is expressed most highly in agouti-related protein (AgRP)/neuropeptide Y (NPY) neurons of the hypothalamic arcuate nucleus and regulates feeding, energy balance, and metabolism (<xref rid="r4" ref-type="bibr">4</xref>). In extrahypothalamic regions, GHSR<sub>1a</sub> is expressed predominantly in the hippocampus, where it regulates learning and cognition (<xref rid="r5" ref-type="bibr">5</xref>), and in dopaminergic midbrain neurons, including the mesolimbic dopamine (DA) neurons of the ventral tegmental area (VTA) and nigrostriatal DA neurons of the substantia nigra pars compacta (SNc) (<xref rid="r6" ref-type="bibr">6</xref>, <xref rid="r7" ref-type="bibr">7</xref>). Within DAergic cells, GHSR<sub>1a</sub> acts as a DA neuromodulator through its effect(s) on neuronal firing rate and DA release probability, biochemical processes that influence locomotion, reward-seeking behavior, and cellular health/neuroprotection (<xref rid="r6" ref-type="bibr">6</xref>, <xref rid="r8" ref-type="bibr">8</xref>, <xref rid="r9" ref-type="bibr">9</xref>).</p><p>Disruptions to central nervous system (CNS) DA homeostasis can lead to psychiatric, neurological, and neurodegenerative conditions (<xref rid="r10" ref-type="bibr">10</xref>). While DA-directed pharmacotherapies (e.g., levodopa, DA receptor agonists/antagonists) may benefit patients initially, these approaches often produce unacceptable side effects when administered chronically (<xref rid="r11" ref-type="bibr">11</xref>, <xref rid="r12" ref-type="bibr">12</xref>). These unwanted consequences are due, in part, to the challenges of developing selective DA receptor modulators, as well as the inability of these therapeutic strategies to fully restore DA signaling to healthy, homeostatic levels. Accordingly, endogenous DA neuromodulators, such as the ghrelin-GHSR<sub>1a</sub> system, may provide a more fine-tuned and safer pharmacological means to normalize the dysfunctional DA signaling underlying brain disorders of mood, cognition, or movement, including addiction, Alzheimer&#x02019;s disease (AD), and/or Parkinson's disease (PD) (<xref rid="r13" ref-type="bibr">13</xref>, <xref rid="r14" ref-type="bibr">14</xref>).</p><p>In peripheral tissue, GHSR<sub>1a</sub> is essential for a diverse array of physiological processes, including glucose-insulin homeostasis, gastrointestinal motility, cardiovascular health, inflammation, and tissue growth and repair (<xref rid="r15" ref-type="bibr">15</xref>). In contrast, GHSR<sub>1a</sub> activity in the CNS appears less well-defined and may be species- and disorder-dependent (<xref rid="r16" ref-type="bibr">16</xref>, <xref rid="r17" ref-type="bibr">17</xref>). For instance, GHSR<sub>1a</sub>(s) expressed in blood&#x02013;brain barrier (BBB)&#x02013;protected regions, including the VTA and SNc, may be poorly accessible to the GHSR<sub>1a</sub>-active form of circulating ghrelin (acyl-ghrelin) and many synthetic GHSR<sub>1a</sub> agonists when administered peripherally (<xref rid="r18" ref-type="bibr">18</xref>). Conversely, the hypothalamus and brainstem are surrounded by fenestrated capillaries that enable circulating acyl-ghrelin to reach GHSR<sub>1a</sub>(s) expressed in these regions (<xref rid="r17" ref-type="bibr">17</xref>). Thus, GHSR<sub>1a</sub>-targeted neurotherapeutics for DA-based brain disorders must be 1) BBB penetrant in order to modulate hippocampal, mesolimbic, and/or nigrostriatal GHSR<sub>1a</sub> functions as well as 2) efficacious and bearing a selective therapeutic profile that minimizes on- and off-target side effects.</p><p>GHSR<sub>1a</sub> signals principally through G&#x003b1;<sub>q/11</sub>, but it is also capable of engaging heterotrimeric G proteins within the G&#x003b1;<sub>i/o</sub> and G&#x003b1;<sub>12/13</sub> families (<xref rid="r19" ref-type="bibr">19</xref>). In addition, GHSR<sub>1a</sub> elicits &#x003b2;-arrestin (&#x003b2;arr)&#x02013;dependent cellular responses in a temporally and spatially distinct manner from G protein&#x02013;mediated signaling, including GHSR<sub>1a</sub> desensitization, internalization, endocytic trafficking and recycling, and the activation of kinases and transcription factors (<xref rid="r20" ref-type="bibr">20</xref>, <xref rid="r21" ref-type="bibr">21</xref>). Thus, GHSR<sub>1a</sub>-directed cellular responses vary according to the extent by which each pathway is selectively activated (ligand selectivity) and modulated downstream (pathway selectivity) (<xref rid="r22" ref-type="bibr">22</xref><xref rid="r23" ref-type="bibr"/>&#x02013;<xref rid="r24" ref-type="bibr">24</xref>). Most notably, point mutations to adjacent amino acids of the GHSR<sub>1a</sub> intracellular loop 2 (ICL2), located near the highly conserved E/DRY motif, induce functionally selective G protein or &#x003b2;arr signaling (<xref rid="r20" ref-type="bibr">20</xref>, <xref rid="r21" ref-type="bibr">21</xref>). Thus, it may be possible to pharmacologically stabilize GHSR<sub>1a</sub> into a conformation that selectively activates signaling through one or more of these pathways.</p><p>In this study, we present the synthesis and characterization of a G&#x003b1;<sub>q</sub>-biased GHSR<sub>1a</sub> agonist, <bold>N8279</bold> (NCATS-SM8864), that contains a 2-carboxamide-3-benzoyl-4-chromenone backbone. In vitro and in silico analyses reveal that <bold>N8279</bold> is functionally selective at GHSR<sub>1a</sub>, and its activity is mediated, at least in part, by extracellular loop 2 (ECL2) and related determinants in the receptor extracellular domain (ECD). In mice, <bold>N8279</bold> readily penetrates the BBB and reaches pharmacologically active levels in brain for extended, druggable periods of time. In vivo efficacy studies show that <bold>N8279</bold> attenuates hyperlocomotion in DA transporter (DAT) knockout (KO) and cocaine-sensitized C57BL/6J mice&#x02014;both mouse models of hyperDAergia&#x02014;but it does not affect novelty-related locomotor activity in inbred C57BL/6J mice under normal physiological conditions. Collectively, our findings support that functional selectivity is a promising strategy when designing GHSR<sub>1a</sub> treatments that target pathophysiological changes in CNS DA homeostasis.</p><sec sec-type="results" id="s1"><title>Results</title><sec id="s2"><title>Discovery of a GHSR<sub>1a</sub>-Selective Small Molecule, N8279, by High-Throughput GHSR<sub>1a</sub> Screening and Structural Characterization.</title><p>To discover biased GHSR<sub>1a</sub> ligands, a cell-based, human GHSR<sub>1a</sub>/&#x003b2;arr1 chemiluminescent assay (DiscoverX, PathHunter) was used to screen &#x0223c;47,000 compounds from the Sytravon library and the National Center for Advancing Translational Sciences (NCATS) pharmacological collection (NPC) (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S1<italic toggle="yes">A</italic></ext-link>). We identified 36 hits (0.09% hit rate) with activities greater than 50% of the activity shown by the full length, human acyl-ghrelin peptide (1&#x02013;28, amino acids) (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S2</ext-link>). Structure-cluster analysis of the hits revealed six chemical scaffolds from the 36 compounds. The hit compounds were reassessed in secondary assays for G&#x003b1;<sub>q/11</sub>-dependent, intracellular Ca<sup>2+</sup> mobilization (iCa<sup>2+</sup>) and &#x003b2;arr2<sup>GFP</sup> (green fluorescent protein) translocation (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Table S1</ext-link>). From these experiments, NCGC141956 (<bold>N1956</bold>) (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S1<italic toggle="yes">B</italic> and Table S1</ext-link>) was selected for further characterization based on its submicromolar potency and full efficacy relative to the unbiased, small molecule GHSR<sub>1a</sub> agonist, L692,585 (L585). A further directed library screen of commercial <bold>N1956</bold> analogs identified NCGC00136164 (<bold>N6164</bold>), which unexpectedly, was determined to be a G&#x003b1;<sub>q/11</sub>-biased GHSR<sub>1a</sub> agonist relative to &#x003b2;arr2 translocation (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Table S1</ext-link>). However, the activity of <bold>N1956</bold> and <bold>N6164</bold> could not be confirmed upon resynthesizing these molecules. A liquid chromatography-mass spectrometer (LC-MS) examination of the dimethyl sulfoxide (DMSO) aliquots used in the screening campaign disclosed impurities within <bold>N1956</bold> and <bold>N6164</bold> solutions, corresponding to oxidated derivatives of the 1-phenyl-chromeno-pyrrole-dione scaffold. Further characterization, investigation using NMR and MS methods (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Table S2</ext-link>), and resynthesis of pure oxidated products resulted in the determination of the active molecule, <bold>N8279</bold> (NCATS-SM8864) (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">A</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S1<italic toggle="yes">C</italic></ext-link>), which contains a 2-carboxamide-3-benzoyl-4-chromenone backbone. In solution, <bold>N8279</bold> equilibrates between open and closed conformers, which in specific solvents and conditions can be observed by <sup>1</sup>H NMR (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Table S2</ext-link>). The structure of the active, open form of <bold>N8279</bold> was confirmed by single crystal X-ray diffraction (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">B</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Table S2</ext-link>).</p><fig position="float" id="fig01" fig-type="featured"><label>Fig. 1.</label><caption><p><bold>N8279</bold> is a potent agonist of GHSR<sub>1a</sub>-mediated G&#x003b1;<sub>q</sub> signaling. <bold>N8279</bold> (<italic toggle="yes">A</italic>) 2D structure and (<italic toggle="yes">B</italic>) structure determined by single crystal X-ray diffraction. (<italic toggle="yes">C</italic>) <bold>N8279</bold> (1 &#x003bc;M) selectivity for human GHSR<sub>1a</sub> plotted versus onefold (blue line) and &#x02265;3-fold (dotted purple line) activity above baseline. (<italic toggle="yes">D</italic>) Linear regression analysis of &#x003b2;arr-based Tango assay results for GPCRome with each point XY corresponding to a distinct receptor and its coordinates defined by X = average of replicates 1 and 2 and Y = average of replicates 3 and 4. (<italic toggle="yes">E</italic>) [<sup>125</sup>I]ghrelin competition binding in hGHSR<sub>1a</sub><sup>WT</sup>-expressing HEK293/T cells (unlabeled ghrelin curve, black; <bold>N8279</bold> curve, red). Data were normalized to vehicle conditions within each experiment and pooled data normalized to the unlabeled (cold) ghrelin <italic toggle="yes">Top</italic> (100%) and <italic toggle="yes">Bottom</italic> (0%). (<italic toggle="yes">F</italic>) iCa<sup>2+</sup> in hGHSR<sub>1a</sub><sup>WT</sup> and miAeq-expressing HEK293/N cells after treatment with ghrelin (black), MK-0677 (green), L585 (blue), or <bold>N8279</bold> (red). <italic toggle="yes">Bottom</italic> and <italic toggle="yes">Top</italic> parameters were constrained to 0% and 100% of ghrelin (% reference); ghrelin and <bold>N8279</bold>
<italic toggle="yes">h</italic> &#x0003e; 1. (<italic toggle="yes">G</italic>) Ghrelin-induced iCa<sup>2+</sup> with concomitant <bold>N8279</bold> treatment. Data are normalized to the vehicle E<sub>max</sub> (100%) and the image displays best-fit three- or four-parameter regressions for each condition. (<italic toggle="yes">H</italic>) G&#x003b1;<sub>q</sub> dissociation (TRUPATH) in hGHSR<sub>1a</sub><sup>WT</sup>-expressing HEK293/T cells. <italic toggle="yes">Bottom</italic> and <italic toggle="yes">Top</italic> parameters were constrained to 0% and 100% of ghrelin (% reference) and the <italic toggle="yes">h</italic> shared (<italic toggle="yes">P</italic> &#x0003e; 0.05). (<italic toggle="yes">I</italic>&#x02013;<italic toggle="yes">K</italic>) Ghrelin, <bold>N8279</bold>, and L585 heat map (<italic toggle="yes">I</italic>); yellow&#x02014;higher potency, blue&#x02014;lower potency or inactivity; (pEC<sub>50</sub>) potencies (<italic toggle="yes">J</italic>) and max efficacies (10 &#x003bc;M) (<italic toggle="yes">K</italic>) at different G proteins derived from curves in <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S4</ext-link>. Statistical differences are derived from Dunnett&#x02019;s multiple comparisons relative to each ligand&#x02019;s G&#x003b1;<sub>q</sub> response. *<italic toggle="yes">P</italic> &#x0003c; 0.05, **<italic toggle="yes">P</italic> &#x0003c; 0.01, ***<italic toggle="yes">P</italic> &#x0003c; 0.001, ****<italic toggle="yes">P</italic> &#x0003c; 0.0001. All data represent the mean &#x000b1; SEM from multiple independent experiments.</p></caption><graphic xlink:href="pnas.2112397119fig01" position="float"/></fig><p>To determine target selectivity, <bold>N8279</bold> activity was evaluated across &#x0201c;the 320 receptor, human GPCRome&#x0201d; by high-throughput screening with a &#x003b2;arr2 recruitment assay (Tango) (<xref rid="r25" ref-type="bibr">25</xref>). Hits were defined as &#x02265;3-fold activation above baseline. <bold>N8279</bold> stimulated &#x0223c;6-fold activation at GHSR<sub>1a</sub> and did not exceed &#x02265;3-fold activation at any other GPCR (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">C</italic></xref>). The assay quality can be assessed by plotting duplicate, independent trial averages (derived from four independent wells) for each receptor as a point (X, Y). The corresponding plot of points for an ideal assay would be fit by a regression line with the slope = 1. A plot of the assay points produced a regression line with slope of 0.98 (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">D</italic></xref>) and is shown with its accompanying 99% prediction band that contains GHSR<sub>1a</sub> as the only hit. Next, the relative affinity of <bold>N8279</bold> for the hGHSR<sub>1a</sub><sup>WT</sup> (GHSR<sub>1a</sub>) was determined by radioligand binding with [<sup>125</sup>I]ghrelin. Initial saturation studies confirmed that [<sup>125</sup>I]ghrelin bound GHSR<sub>1a</sub> asymptotically with nanomolar affinity (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S3<italic toggle="yes">A</italic></ext-link>). Subsequent competition binding using [<sup>125</sup>I]ghrelin at its ~K<sub>d</sub> demonstrate that both unlabeled ghrelin and <bold>N8279</bold> displace [<sup>125</sup>I]ghrelin from GHSR<sub>1a</sub> with high and relatively low affinity, respectively (IC<sub>50</sub> [nM] = 2.5 and 1,300) (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">E</italic></xref>).</p></sec><sec id="s3"><title>N8279 Is a Potent Agonist of GHSR<sub>1a</sub>-Mediated G&#x003b1;<sub>q</sub> Signaling.</title><p>GHSR<sub>1a</sub> primarily couples to G&#x003b1;<sub>q/11</sub>, leading to phospholipase C-&#x003b2;-dependent inositol trisphosphate generation and iCa<sup>2+</sup> (<xref rid="r20" ref-type="bibr">20</xref>). Initial structure-activity relationship screening suggested that the <bold>N8279</bold> precursors <bold>N1965</bold> and <bold>N6164</bold> may exhibit G&#x003b1;<sub>q/11</sub> bias (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S1<italic toggle="yes">B</italic> and Table S1</ext-link>). To confirm this with the active congener, <bold>N8279</bold> (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S1 <italic toggle="yes">A</italic>&#x02013;<italic toggle="yes">C</italic> and Table S2</ext-link>), we performed concentration&#x02013;response (C/R) analyses in cells stably expressing GHSR<sub>1a</sub> and an iCa<sup>2+</sup> reporter (<xref rid="r21" ref-type="bibr">21</xref>). The results show that <bold>N8279</bold> is nearly an order of magnitude (8.9-fold) more potent than the endogenous ligand ghrelin and is a full agonist (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">F</italic></xref>). <bold>N8279</bold> was only 3.4- and 5.3-fold less potent than the high-affinity, unbiased small molecule agonists L585 and MK-0677, respectively (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">F</italic></xref>). Consistent with prior work (<xref rid="r26" ref-type="bibr">26</xref>), ghrelin was relatively weak at stimulating iCa<sup>2+</sup> compared to its GHSR<sub>1a</sub> binding affinity (<xref rid="fig01" ref-type="fig">Fig. 1 <italic toggle="yes">E</italic> and <italic toggle="yes">F</italic></xref>; Ref. <xref rid="r26" ref-type="bibr">26</xref>). Conversely, the iCa<sup>2+</sup> half-maximal effective concentration (EC<sub>50</sub>) of <bold>N8279</bold> was 41-fold more potent than its GHSR<sub>1a</sub> binding IC<sub>50</sub> (<xref rid="fig01" ref-type="fig">Fig. 1 <italic toggle="yes">E</italic> and <italic toggle="yes">F</italic></xref>), suggesting possible allosteric activity (<xref rid="r26" ref-type="bibr">26</xref>). Only ghrelin and <bold>N8279</bold> each had a Hill slope (<italic toggle="yes">h</italic>) &#x0003e; 1, suggesting that two or more molecules or GHSR<sub>1a</sub> binding sites are required for these ligands to elicit full efficacy in this cell system (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">F</italic></xref>).</p><p>The iCa<sup>2+</sup> evoked by EC<sub>80</sub>
<bold>N8279</bold> (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S3<italic toggle="yes">B</italic></ext-link>), ghrelin (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S3<italic toggle="yes">C</italic></ext-link>), or L585 (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S3<italic toggle="yes">D</italic></ext-link>) was competitively inhibited by the GHSR<sub>1a</sub> antagonists YIL781 and JMV2959, supporting GHSR<sub>1a</sub>-dependent effects. For each agonist, YIL781 was the more potent inhibitor (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S3 <italic toggle="yes">B</italic>&#x02013;<italic toggle="yes">D</italic></ext-link>). To determine whether <bold>N8279</bold> elicits GHSR<sub>1a</sub>-mediated iCa<sup>2+</sup> through G&#x003b1;<sub>q/11</sub> specifically, we tested iCa<sup>2+</sup> in G&#x003b1;<sub>q/11</sub> KO and wild-type (WT) cells (<xref rid="r27" ref-type="bibr">27</xref>) and confirmed that 10 &#x003bc;M ghrelin-, L585-, and <bold>N8279</bold>-induced iCa<sup>2+</sup> was abolished (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S3<italic toggle="yes">E</italic></ext-link>).</p><p>We next evaluated the effect of <bold>N8279</bold> on ghrelin-induced iCa<sup>2+</sup> signaling to test for ago-allosteric activity. Parenthetically, ago-allosteric agonists interact with topographically distinct receptor sites (allosteric) from the endogenous ligand (orthosteric), elicit agonist behavior on their own, and cooperatively act as a positive (PAM), negative (NAM), or silent (SAM) modulator of orthosteric ligand affinity, potency, and/or efficacy (<xref rid="r28" ref-type="bibr">28</xref>). As expected, <bold>N8279</bold> displayed intrinsic GHSR<sub>1a</sub> agonism on its own (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">G</italic></xref>, left dashes). At 10 &#x003bc;M, <bold>N8279</bold> produced an &#x0223c;3-fold increase in ghrelin&#x02019;s potency but did not reach statistical significance (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">G</italic></xref>). <bold>N8279</bold> additively increased &#x0223c;EC<sub>20</sub> ghrelin (100 nM) efficacy in a concentration-dependent manner (Fig. <italic toggle="yes">G</italic>, right dashes/upward arrow) and marginally increased the ghrelin E<sub>max</sub> (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">G</italic></xref>, upward arrow), supporting weak ago-PAM activity (<xref rid="r29" ref-type="bibr">29</xref>). To assess reciprocal cooperativity, we tested iCa<sup>2+</sup> upon concomitant treatment of EC<sub>25</sub> MK-0677 or EC<sub>50</sub> ghrelin and an <bold>N8279</bold> C/R. In the presence of these orthosteric agonists, <bold>N8279</bold> was equipotent relative to <bold>N8279</bold> alone; however, the <italic toggle="yes">h</italic> of <bold>N8279</bold> alone (<italic toggle="yes">h</italic> &#x0003e; 1) was reduced to unity (<italic toggle="yes">h</italic> = 1) (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S3<italic toggle="yes">F</italic></ext-link>). These findings indicate that <bold>N8279</bold> evokes a complete and potent signaling response despite simultaneous occupancy of the GHSR<sub>1a</sub> orthosteric binding pocket.</p><p>To model how <bold>N8279</bold> could co-occupy the monomeric GHSR<sub>1a</sub> with ghrelin, we employed molecular docking with an NMR-based homology model of the ghrelin-bound GHSR<sub>1a</sub> (<xref rid="r30" ref-type="bibr">30</xref>). Concomitant <bold>N8279</bold> docking to ghrelin (1&#x02013;17, amino acids)&#x02013;bound GHSR<sub>1a</sub> suggests that the propylamine moiety of <bold>N8279</bold> could form a strong ionic bond with a negatively charged ECL2 (Asp191) (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S3<italic toggle="yes">G</italic></ext-link>). In this pose, <bold>N8279</bold> was found to bind GHSR<sub>1a</sub> atop ghrelin, enabling ghrelin&#x02019;s N terminus to insert into the deep orthosteric binding pocket and interact with Glu124 in transmembrane domain (TM)-III, consistent with prior models and the proposed agonist-induced activation mechanism of GHSR<sub>1a</sub> (<xref rid="r30" ref-type="bibr">30</xref>, <xref rid="r31" ref-type="bibr">31</xref>). Thus, <bold>N8279</bold> may exhibit state-dependent allosteric GHSR<sub>1a</sub> binding by anchoring to ECL2.</p></sec><sec id="s4"><title>N8279 Biases GHSR<sub>1a</sub> Toward G&#x003b1;<sub>q</sub> Coupling over Other G&#x003b1; Subunits.</title><p>To evaluate the effect of <bold>N8279</bold> on G&#x003b1;<sub>q</sub> proximal to the GHSR<sub>1a</sub>, we employed parallel NanoBiT- (<xref rid="r32" ref-type="bibr">32</xref>) and bioluminescence resonance energy transfer (BRET, TRUPATH; Ref. <xref rid="r33" ref-type="bibr">33</xref>)&#x02013;based heterotrimeric G protein subunit dissociation approaches. In both assays, <bold>N8279</bold> was a full agonist for G&#x003b1;<sub>q</sub> activation with a potency comparable to that of iCa<sup>2+</sup> (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">H</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Figs. S1<italic toggle="yes">F</italic> and S3<italic toggle="yes">H</italic></ext-link>). In NanoBiT-G&#x003b1;<sub>q</sub> assays, <bold>N8279</bold> and ghrelin potencies were statistically equivalent (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S3<italic toggle="yes">H</italic></ext-link>). In BRET-G&#x003b1;<sub>q</sub> assays, <bold>N8279</bold> was 6.1- and 1.7-fold less potent than ghrelin and L585, respectively (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">H</italic></xref>). In contrast to iCa<sup>2+</sup> assays (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">F</italic></xref>), the <italic toggle="yes">h</italic> was &#x0003c;1 for each agonist. These differences may be due to distinct G protein subunit composition/ratios and/or response sensitivities between these assays (see <xref rid="s10" ref-type="sec"><italic toggle="yes">Materials and Methods</italic></xref>). Notably, ghrelin was &#x0223c;30 to 50-fold more potent at activating G&#x003b1;<sub>q</sub> proximally than eliciting downstream iCa<sup>2+</sup> (<xref rid="fig01" ref-type="fig">Fig. 1 <italic toggle="yes">F</italic> and <italic toggle="yes">H</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S3<italic toggle="yes">H</italic></ext-link>), consistent with a prior report (<xref rid="r26" ref-type="bibr">26</xref>). These findings suggest that in these cell systems, low ghrelin concentrations are sufficient to dissociate the heterotrimeric G&#x003b1;<sub>q</sub> complex, whereas high ghrelin concentrations are required to fully engage downstream GHSR<sub>1a</sub> signaling, as seen with other homodimeric GPCRs (<xref rid="r34" ref-type="bibr">34</xref>). Alternatively, ghrelin could elicit G&#x003b1;<sub>q</sub>-independent signaling that counter regulates iCa<sup>2+</sup> in this assay. Collectively, these results demonstrate that <bold>N8279</bold> is a potent agonist of G&#x003b1;<sub>q</sub> signaling at GHSR<sub>1a</sub>.</p><p>In an independent set of experiments, we evaluated <bold>N8279</bold> signaling through other G proteins to compare to G&#x003b1;<sub>q</sub>. We selectively tested G&#x003b1; subunits that are expressed highly in midbrain DAergic neurons (<xref rid="r35" ref-type="bibr">35</xref>) and/or reported previously to exhibit GHSR<sub>1a</sub> coupling, including G&#x003b1;<sub>sS</sub> (G&#x003b1;<sub>s</sub>), G&#x003b1;<sub>i1</sub>, G&#x003b1;<sub>i2</sub>, G&#x003b1;<sub>oA</sub>, G&#x003b1;<sub>12</sub>, and G&#x003b1;<sub>13</sub> (<xref rid="r19" ref-type="bibr">19</xref>, <xref rid="r23" ref-type="bibr">23</xref>, <xref rid="r36" ref-type="bibr">36</xref>). Relative to G&#x003b1;<sub>q</sub>, ghrelin potency was statistically equivalent for each G&#x003b1;<sub>i/o</sub> and was reduced moderately for G&#x003b1;<sub>12</sub> and G&#x003b1;<sub>13</sub> (<xref rid="fig01" ref-type="fig">Fig. 1 <italic toggle="yes">I</italic> and <italic toggle="yes">J</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S4</ext-link>). Ghrelin did not activate G&#x003b1;<sub>s</sub>, consistent with a prior study (<xref rid="r19" ref-type="bibr">19</xref>). L585 displayed a similar profile, except that it had reduced potency at G&#x003b1;<sub>i1</sub> and only a statistical trend for reduced potency at G&#x003b1;<sub>12</sub>. In contrast, <bold>N8279</bold> potency was significantly reduced to concentrations &#x0003e;1 &#x003bc;M for every G&#x003b1; (<xref rid="fig01" ref-type="fig">Fig. 1 <italic toggle="yes">I</italic> and <italic toggle="yes">J</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S4</ext-link>), suggesting bias toward G&#x003b1;<sub>q</sub> coupling. Although <bold>N8279</bold> and L585 showed statistically equipotent activation of G&#x003b1;<sub>s</sub>, their maximal efficacies (10 &#x003bc;M) at G&#x003b1;<sub>s</sub> were markedly reduced (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">K</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S4</ext-link>). Moreover, <bold>N8279</bold> maximum efficacy was significantly reduced at G&#x003b1;<sub>12/13</sub> compared to ghrelin and L585, as well as at G&#x003b1;<sub>i2</sub> and G&#x003b1;<sub>oA</sub> compared to L585 (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">K</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S4</ext-link>). For each ligand, maximal efficacy was reduced at every G&#x003b1; relative to their respective effect on G&#x003b1;<sub>q</sub> (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">K</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S4</ext-link>).</p><p>Together, the data in <xref rid="fig01" ref-type="fig">Fig. 1</xref> support that <bold>N8279</bold> is a potent GHSR<sub>1a</sub> agonist with functional selectivity toward G&#x003b1;<sub>q</sub>. All pharmacological results (IC<sub>50</sub>, K<sub>i</sub>, logEC<sub>50</sub>, E<sub>max</sub>, <italic toggle="yes">h</italic> &#x000b1; SEM) and statistical comparisons for <xref rid="fig01" ref-type="fig">Fig. 1</xref> are shown in <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Table S3</ext-link>.</p></sec><sec id="s5"><title>N8279 Recruits &#x003b2;arr2 to GHSR<sub>1a</sub> More Weakly than Ghrelin.</title><p>Having established that <bold>N8279</bold> is a potent activator of G&#x003b1;<sub>q</sub> signaling, we next assessed its effect on GHSR<sub>1a</sub>-mediated &#x003b2;arr recruitment first using a NanoBiT-based approach. Cells expressing a fixed ratio of GHSR<sub>1a</sub><sup>LgBiT</sup> and <sup>SmBiT</sup>&#x003b2;arr2 were treated with ghrelin, L585, or <bold>N8279</bold>. Here, <bold>N8279</bold> was &#x0223c;20-fold less potent than ghrelin, and it approached full agonism (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">A</italic></xref>). Conversely, L585 recruited &#x003b2;arr2 with moderately higher potency and equivalent efficacy to ghrelin (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">A</italic></xref>), and comparatively, <bold>N8279</bold> was &#x0223c;43-fold less potent than L585 in this assay. Thus, <bold>N8279</bold> is a weaker agonist of GHSR<sub>1a</sub>-&#x003b2;arr2 recruitment than ghrelin and L585, supporting that it exhibits functional selectivity toward G&#x003b1;<sub>q</sub> over &#x003b2;arr coupling (<xref rid="fig01" ref-type="fig">Fig. 1</xref>).</p><fig position="float" id="fig02" fig-type="figure"><label>Fig. 2.</label><caption><p><bold>N8279</bold> is a weak activator of GHSR<sub>1a</sub>-mediated, &#x003b2;arr2-dependent cellular responses relative to ghrelin. (<italic toggle="yes">A</italic>) Peak <sup>SmBiT</sup>&#x003b2;arr2 recruitment (average, 0 to 5 min) to hGHSR<sub>1a</sub><sup>LgBiT</sup> in HEK293/T cells. Data were baseline normalized within each experiment, then to the ghrelin E<sub>max</sub> (% reference). (<italic toggle="yes">B</italic>) hGHSR<sub>1a</sub><sup>LgBiT</sup>-<sup>SmBiT</sup>&#x003b2;arr2 saturation after treatment with ghrelin (100 nM, black) or <bold>N8279</bold> (100 nM, light red; 200 nM, dark red). Hyperbola were fit by one-site regression to derive a B<sub>max</sub> (BiT<sub>max</sub>) and K<sub>d</sub> (BiT<sub>d</sub>), then normalized to the ghrelin BiT<sub>max</sub> (100%). (<italic toggle="yes">B</italic>, <italic toggle="yes">Inset</italic>) Ghrelin and N8279 BiT<sub>d</sub> values derived from <italic toggle="yes">B</italic> and analyzed by one-way analysis of variance (ANOVA) followed by Sidak's multiple comparisons. (<italic toggle="yes">C</italic>) [<sup>125</sup>I]ghrelin competition binding in HEK293/T cells expressing hGHSR<sub>1a</sub><sup>L149G</sup>. Data were normalized as in <xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">E</italic></xref>. (<italic toggle="yes">D</italic>) Maximum <sup>Venus</sup>&#x003b2;arr2 recruitment (over 60 min) to hGHSR<sub>1a</sub><sup>WT</sup> or hGHSR<sub>1a</sub><sup>L149G</sup> in HEK293/T cells. Data were baseline normalized within each experiment, then the ghrelin-WT E<sub>max</sub> (% reference). (<italic toggle="yes">E</italic>) EC<sub>80</sub> ghrelin (40 nM)&#x02013;induced <sup>SmBiT</sup>&#x003b2;arr2 recruitment to hGHSR<sub>1a</sub><sup>LgBiT</sup> after pretreatment (5 min) with YIL781, JMV2959, or <bold>N8279</bold>. The 100% point represents EC<sub>80</sub> ghrelin alone and the 0% line represents baseline. (<italic toggle="yes">F</italic>) Representative images of vehicle-, ghrelin (100 nM)&#x02013;, or <bold>N8279</bold> (100 nM)&#x02013;induced &#x003b2;arr2 translocation (45 min, 37&#x02009;&#x000b0;C) in U2OS cells expressing hGHSR<sub>1a</sub><sup>WT</sup> and &#x003b2;arr2<sup>GFP</sup>. (<italic toggle="yes">G</italic>) hGHSR<sub>1a</sub><sup>WT</sup> internalization in HEK293/T cells (45 min, 37&#x02009;&#x000b0;C). Data are expressed as the percentage of GHSR<sub>1a</sub> expression relative to baseline (100%), and pooled data were normalized to the ghrelin <italic toggle="yes">Top</italic> (100%) and <italic toggle="yes">Bottom</italic> (0%) (% reference). (<italic toggle="yes">H</italic>) bBRET-based hGHSR<sub>1a</sub><sup>WT-RLucII</sup> internalization in HEK293/T cells with MyrPalm<sup>Venus</sup>. Data represent the average net BRET (60 min) normalized to baseline within each experiment and then to the ghrelin <italic toggle="yes">Top</italic> (100%) and <italic toggle="yes">Bottom</italic> (0%) (% reference). (<italic toggle="yes">I</italic>) bBRET-based hGHSR<sub>1a</sub><sup>WT-RLucII</sup> trafficking in HEK293/T cells with 2&#x000d7;FYVE<sup>Venus</sup>. Data represent the average net BRET (60 min) normalized to the ghrelin E<sub>max</sub> (% reference). (<italic toggle="yes">J</italic>) GHSR<sub>1a</sub> trafficking E<sub>max</sub> over 120 min as derived from <italic toggle="yes">I</italic>. (<italic toggle="yes">K</italic>) SRF-RE&#x02013;mediated transcription in HEK293/T cells expressing hGHSR<sub>1a</sub><sup>WT</sup>. Data were normalized to the ghrelin E<sub>max</sub> (% reference). (<italic toggle="yes">L</italic>) <bold>N8279</bold> bias factor (RA<sub>i</sub> model) with &#x003b2; (log<sub>10</sub>) quantified using ghrelin (black/gray) or L585 (blue) as reference ligands. All data represent the mean &#x000b1; SEM from multiple independent experiments. ***<italic toggle="yes">P</italic> &#x0003c; 0.001; **<italic toggle="yes">P</italic> &#x0003c; 0.01; *<italic toggle="yes">P</italic> &#x0003c; 0.05; n.s. (nonsignificant), <italic toggle="yes">P</italic> &#x0003e; 0.05.</p></caption><graphic xlink:href="pnas.2112397119fig02" position="float"/></fig><p>To further test this hypothesis, cells expressing a variable ratio of GHSR<sub>1a</sub><sup>LgBiT</sup> and <sup>SmBiT</sup>&#x003b2;arr2 were treated with ghrelin (100 nM) or &#x0223c;EC<sub>80</sub>
<bold>N8279</bold> for G&#x003b1;<sub>q</sub> signaling (100 to 200 nM; <xref rid="fig01" ref-type="fig">Fig. 1 <italic toggle="yes">F</italic> and <italic toggle="yes">H</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S3<italic toggle="yes">H</italic></ext-link>). These analyses revealed that the relative affinity (BiT<sub>d</sub>) of &#x003b2;arr2 for GHSR<sub>1a</sub> was 2- to 2.5-fold weaker in <bold>N8279</bold>-treated cells than in ghrelin-treated cells (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">B</italic></xref>, Inset). Furthermore, in competitive binding studies with the ICL2 mutant GHSR<sub>1a</sub><sup>L149G</sup> (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">C</italic></xref>), a &#x003b2;arr2-biased receptor (<xref rid="r20" ref-type="bibr">20</xref>), the ability of <bold>N8279</bold> to displace [<sup>125</sup>I]ghrelin was diminished and shifted rightward by ~10-fold (IC<sub>50</sub> &#x0003e; 10 &#x003bc;M) relative to GHSR<sub>1a</sub><sup>WT</sup> (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">E</italic></xref>). In contrast, the IC<sub>50</sub> of unlabeled ghrelin for GHSR<sub>1a</sub><sup>L149G</sup> was reduced by only &#x0223c;2-fold compared to GHSR<sub>1a</sub><sup>WT</sup> (<xref rid="fig01" ref-type="fig">Figs. 1<italic toggle="yes">E</italic></xref> and <xref rid="fig02" ref-type="fig">2<italic toggle="yes">C</italic></xref>). A follow-up, BRET-based GHSR<sub>1a</sub><sup>L149G-RLucII</sup>-<sup>Venus</sup>&#x003b2;arr2 recruitment assay further supported distinct properties between ghrelin and <bold>N8279</bold> at the &#x003b2;arr-biased GHSR<sub>1a</sub><sup>L149G</sup>. While GHSR<sub>1a</sub><sup>L149G</sup> reduced the E<sub>max</sub> of ghrelin and <bold>N8279</bold> to similar extents (&#x0223c;35%), the <bold>N8279</bold> potency was reduced by &#x0223c;5-fold, whereas the ghrelin potency was reduced by only &#x0223c;2-fold relative to GHSR<sub>1a</sub><sup>WT</sup> (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">D</italic></xref>). Notably, interassay comparisons revealed that <bold>N8279</bold> was &#x0223c;100-fold less potent than ghrelin in BRET-based GHSR<sub>1a</sub><sup>WT</sup>-&#x003b2;arr2 recruitment assays (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">D</italic></xref>) but only &#x0223c;20-fold less potent in NanoBiT-based measurements (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">A</italic></xref>). This distinction may be due to variations in GHSR<sub>1a</sub>-&#x003b2;arr2 expression ratios, biosensor interaction kinetics, and/or measurement time, e.g., GHSR<sub>1a</sub>-&#x003b2;arr2 expression ratios (BRET = 1:15 versus NanoBiT = 1:1) and measurement durations (BRET = 60 min versus NanoBiT = 5 min). Nonetheless, these findings together suggest that <bold>N8279</bold> stabilizes GHSR<sub>1a</sub> conformations that disfavor GHSR<sub>1a</sub>-&#x003b2;arr2 coupling relative to ghrelin and, reciprocally, that GHSR<sub>1a</sub> conformations preferentially supporting &#x003b2;arr2 coupling (GHSR<sub>1a</sub><sup>L149G</sup>) diminish <bold>N8279</bold>-GHSR<sub>1a</sub> interaction(s).</p><p>Next, we assessed whether <bold>N8279</bold>&#x02014;as an agonist functionally selective for G&#x003b1;<sub>q</sub>&#x02014;could behave as a &#x003b2;arr2 antagonist in the presence of ghrelin. We pretreated cells expressing GHSR<sub>1a</sub><sup>LgBiT</sup> and <sup>SmBiT</sup>&#x003b2;arr2 with increasing concentrations of <bold>N8279</bold> or the antagonists YIL781 or JMV2959, followed by EC<sub>80</sub> ghrelin. <bold>N8279</bold> inhibited ghrelin-induced &#x003b2;arr2 recruitment significantly, but incompletely, in a concentration-dependent manner and was 1.7- and 2.9-fold less potent than JMV2959 and YIL781 (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">E</italic></xref>). These data suggest that <bold>N8279</bold> stabilizes GHSR<sub>1a</sub> conformation(s) that weaken &#x003b2;arr2 coupling in both apo- (<xref rid="fig02" ref-type="fig">Fig. 2 <italic toggle="yes">A</italic>, <italic toggle="yes">B</italic>, and <italic toggle="yes">D</italic></xref>) and ghrelin-bound (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">E</italic></xref>) receptor states.</p></sec><sec id="s6"><title>N8279 Reduces &#x003b2;arr-Dependent Cellular Responses Relative to Ghrelin.</title><p>Qualitative microscopy of U2OS cells expressing GHSR<sub>1a</sub> and &#x003b2;arr2<sup>GFP</sup> showed minimal response to 100 nM <bold>N8279</bold> and displayed diffusely distributed cytosolic &#x003b2;arr2<sup>GFP</sup> similar to vehicle-treated cells (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">F</italic></xref>). Conversely, 100 nM ghrelin&#x02013;treated cells exhibited marked accumulation of cytosolic puncta, indicative of robust &#x003b2;arr2<sup>GFP</sup> translocation and GHSR<sub>1a</sub> endocytosis/trafficking (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">F</italic></xref>). Though ghrelin produced a robust response, the relatively weak response produced by <bold>N8279</bold> in these experiments may reflect differences in engagement with early (e.g., GPCR kinases; Ref. <xref rid="r37" ref-type="bibr">37</xref>) or late molecular mediators of receptor endocytosis and/or endosomal trafficking (<xref rid="r21" ref-type="bibr">21</xref>). Thus, we evaluated ligand-induced GHSR<sub>1a</sub> endocytosis using three independent methods. First, in a quantitative, cell surface enzyme-linked immunosorbent assay (ELISA) approach, both ghrelin and <bold>N8279</bold> stimulated GHSR<sub>1a</sub> internalization in a concentration-dependent manner (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">G</italic></xref>). However, <bold>N8279</bold> internalization potency was reduced by 24-fold, and the efficacy was reduced modestly (&#x0223c;30%) relative to ghrelin (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">G</italic></xref>). Second, we employed a bystander BRET (bBRET)&#x02013;based plasma membrane sensor, MyrPalm<sup>Venus</sup> (<xref rid="r38" ref-type="bibr">38</xref>), and found that <bold>N8279</bold>-induced GHSR<sub>1a</sub> internalization (over 60 min) potency was reduced by 32-fold and efficacy was attenuated by &#x0223c;20% relative to ghrelin (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">H</italic></xref>). Last, the bBRET-based sensor for early endosomes (<xref rid="r21" ref-type="bibr">21</xref>, <xref rid="r39" ref-type="bibr">39</xref>), 2&#x000d7;FYVE<sup>Venus</sup> (<xref rid="r40" ref-type="bibr">40</xref>), showed that <bold>N8279</bold>-induced GHSR<sub>1a</sub> endosomal transit was 32-fold less potent and less efficacious (&#x0223c;35%) than ghrelin over 60 min posttreatment (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">I</italic></xref>). Temporal analyses revealed that <bold>N8279</bold>-stimulated GHSR<sub>1a</sub> endosomal trafficking occurred on a time course similar to ghrelin, albeit with reduced efficacy across the entire 120-min measurement (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">J</italic></xref>).</p><p>&#x003b2;arr2 is required for GHSR<sub>1a</sub>-mediated RhoA GTPase/ROCK signaling (<xref rid="r41" ref-type="bibr">41</xref>), leading to transcriptional activation and cytoskeletal rearrangement by induction of actin polymerization (<xref rid="r20" ref-type="bibr">20</xref>). To test whether <bold>N8279</bold> affects these processes, we utilized the RhoA-dependent transcriptional reporter serum response factor response element (SRF-RE) (<xref rid="r20" ref-type="bibr">20</xref>). Here, <bold>N8279</bold> was a full agonist with mildly increased maximal efficacy relative to ghrelin (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">K</italic></xref>). However, <bold>N8279</bold> potency was reduced &#x0223c;10- to 15-fold relative to L585 and ghrelin, respectively. The enhanced efficacy of <bold>N8279</bold> in these assays compared to <xref rid="fig02" ref-type="fig">Fig. 2 <italic toggle="yes">G</italic>&#x02013;<italic toggle="yes">J</italic></xref> could be a time-dependent effect, in part, due to the 6-h treatment duration (see <xref rid="s10" ref-type="sec"><italic toggle="yes">Materials and Methods</italic></xref>) and/or the partial contribution(s) of G&#x003b1;<sub>12/13</sub> or especially MAPK/ERK signaling to SRF transcription (<xref rid="r20" ref-type="bibr">20</xref>).</p><p>To quantitatively assess <bold>N8279</bold> bias between the G&#x003b1;<sub>q</sub> and &#x003b2;arr2 (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">A</italic></xref>) pathways, we used the intrinsic relative activities (RA<sub>i</sub>) model as described previously (<xref rid="r42" ref-type="bibr">42</xref>). Relative to ghrelin, <bold>N8279</bold> had a proximal (G&#x003b1;<sub>q</sub> dissociation, <xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">H</italic></xref>) bias factor (&#x003b2;) of 0.59 (&#x0223c;4-fold) and a downstream (iCa<sup>2+</sup>, <xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">F</italic></xref>) &#x003b2; of 2.63 (&#x0223c;427-fold) relative to &#x003b2;arr2 recruitment (NanoBiT, <xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">A</italic></xref>) (<xref rid="fig02" ref-type="fig">Fig. 2 <italic toggle="yes">L</italic></xref>, <italic toggle="yes">Left</italic>). Relative to L585, <bold>N8279</bold> had a proximal &#x003b2; of 1.45 (&#x0223c;28-fold) and a downstream &#x003b2; of 1.15 (&#x0223c;14-fold) (<xref rid="fig02" ref-type="fig">Fig. 2 <italic toggle="yes">L</italic></xref>, <italic toggle="yes">Right</italic>). Notably, assay-standardized bias calculations (i.e., G&#x003b1;<sub>q</sub>-&#x003b2;arr2 BRET versus G&#x003b1;<sub>q</sub>-&#x003b2;arr2 NanoBiT) using ghrelin as a reference ligand showed that <bold>N8279</bold> had a proximal &#x003b2; of 1.16 (&#x0223c;14-fold) and 1.36 (&#x0223c;23-fold) when employing paired BRET-G&#x003b1;<sub>q</sub>/BRET-&#x003b2;arr2 or NanoBiT-G&#x003b1;<sub>q</sub>/NanoBiT-&#x003b2;arr2 assays, respectively (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S5</ext-link>). Ultimately, these analyses together support that <bold>N8279</bold> is a G protein&#x02013;biased agonist of both proximal and downstream GHSR<sub>1a</sub>-G&#x003b1;<sub>q</sub> signaling.</p><p>Collectively, the data in <xref rid="fig02" ref-type="fig">Fig. 2</xref> support that <bold>N8279</bold> is a weak agonist of GHSR<sub>1a</sub>-mediated, &#x003b2;arr-dependent signaling relative to ghrelin, and thus, <bold>N8279</bold> is a G protein&#x02013;biased GHSR<sub>1a</sub> agonist. All pharmacological results and statistical comparisons for <xref rid="fig01" ref-type="fig">Fig. 1</xref> are shown in <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Table S4</ext-link>.</p></sec><sec id="s7"><title>GHSR<sub>1a</sub> Mutagenesis and Molecular Docking Suggest an ECD-Dependent, Extended Binding Mode of N8279.</title><p>We next evaluated whether determinants outside the orthosteric binding pocket are required for <bold>N8279</bold> signaling by first using a naturally occurring variant, GHSR<sub>1a</sub><sup>A204E</sup> (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">A</italic></xref>). Substitution of glutamic acid at this ECL2 site abolishes constitutive activity and causes short stature in humans (<xref rid="r43" ref-type="bibr">43</xref>). However, the GHSR<sub>1a</sub><sup>A204E</sup> mutation does not appreciably affect ghrelin binding (affinity) or ghrelin-induced G&#x003b1;<sub>q</sub> signaling (potency) (<xref rid="r43" ref-type="bibr">43</xref>, <xref rid="r44" ref-type="bibr">44</xref>), supporting that it lies outside the orthosteric binding pocket.</p><fig position="float" id="fig03" fig-type="figure"><label>Fig. 3.</label><caption><p><bold>N8279</bold> requires receptor sites and/or conformational states driven by the GHSR<sub>1a</sub> ECD that are distinct from ghrelin. (<italic toggle="yes">A</italic>) Amino acid snake plot of the hGHSR<sub>1a</sub><sup>WT</sup> highlighting Ala204<sup>ECL2</sup> (red) and the Ala204Glu mutation. Ghrelin-induced (<italic toggle="yes">B</italic>) iCa<sup>2+</sup>, (<italic toggle="yes">C</italic>) TRUPATH G<sub>q</sub> dissociation, and (<italic toggle="yes">D</italic>) NanoBiT &#x003b2;arr2 recruitment at hGHSR<sub>1a</sub><sup>WT</sup> (black) or hGHSR<sub>1a</sub><sup>A204E</sup> (purple). <bold>N8279</bold>-induced (<italic toggle="yes">E</italic>) iCa<sup>2+</sup>, (<italic toggle="yes">F</italic>) TRUPATH G&#x003b1;<sub>q</sub> dissociation, and (<italic toggle="yes">G</italic>) NanoBiT &#x003b2;arr2 recruitment at hGHSR<sub>1a</sub><sup>WT</sup> (red) or hGHSR<sub>1a</sub><sup>A204E</sup> (yellow). All data are normalized to the GHSR<sub>1a</sub><sup>WT</sup> E<sub>max</sub>. G&#x003b1;<sub>q</sub> dissociation and &#x003b2;arr2 recruitment assays are also baseline normalized. (<italic toggle="yes">H</italic>) Superimposition of the ghrelin-bound model structure (blue) with the antagonist-bound X-ray crystal structure (6KO5, green). (<italic toggle="yes">I</italic>) Proposed GHSR<sub>1a</sub><sup>DTP</sup> (red) and GHSR<sub>1a</sub><sup>ECD</sup> (blue) binding pockets in the ghrelin-bound model. Gln120, Glu124, Phe279, Arg283, and Phe309 constitute the canonical orthosteric GHSR<sub>1a</sub><sup>DTP</sup> pocket; mutations to these residues cause significant loss of ghrelin and orthosteric agonist efficacy (<xref rid="r46" ref-type="bibr">46</xref>). Asp99, Cys198, and Asn305 constitute predicted interaction sites within the GHSR<sub>1a</sub><sup>ECD</sup> binding pocket of the ghrelin-bound model. (<italic toggle="yes">J</italic>) <bold>N8279</bold> docking pose (green) in GHSR<sub>1a</sub><sup>DTP</sup>. (<italic toggle="yes">K</italic>) <bold>N8279</bold> docking pose (green) in GHSR<sub>1a</sub>
<sup>ECD</sup>. Dash lines indicate hydrogen bonds (yellow), ionic interactions (pink) and &#x003c0;&#x02013;&#x003c0; stacking interactions (turquoise), or halogen bonds (purple). (<italic toggle="yes">L</italic>) Snake plot of hGHSR<sub>1a</sub><sup>WT</sup> with experimentally mutated residues: D99A (blue), E197A (green), R199A (orange), P200A (purple), A204E (yellow), N305A (teal), and Glu124 and Cys198 (gray, mutations not made). (<italic toggle="yes">M</italic>) Ghrelin and <bold>N8279</bold> G&#x003b1;<sub>q</sub> dissociation (TRUPATH) and (<italic toggle="yes">N</italic>) iCa<sup>2+</sup> pEC<sub>50</sub> and E<sub>max</sub> at GHSR<sub>1a</sub> mutants shown in <italic toggle="yes">L</italic>, derived from <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S6</ext-link>. All data represent the mean &#x000b1; SEM from multiple independent experiments.</p></caption><graphic xlink:href="pnas.2112397119fig03" position="float"/></fig><p>Consistent with prior studies (<xref rid="r43" ref-type="bibr">43</xref>, <xref rid="r44" ref-type="bibr">44</xref>), GHSR<sub>1a</sub><sup>A204E</sup> showed no basal iCa<sup>2+</sup> activity (<xref rid="fig03" ref-type="fig">Fig. 3 <italic toggle="yes">B</italic> and <italic toggle="yes">C</italic></xref>); surface expression was reduced by &#x0223c;50% (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S6<italic toggle="yes">A</italic></ext-link>); it had minimal-to-no effect on ghrelin-stimulated G&#x003b1;<sub>q</sub> dissociation and iCa<sup>2+</sup> (<xref rid="fig03" ref-type="fig">Fig. 3 <italic toggle="yes">B</italic> and <italic toggle="yes">C</italic></xref>); and ghrelin-stimulated &#x003b2;arr2 recruitment efficacy, but not potency, was reduced (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">D</italic></xref>; Ref. <xref rid="r44" ref-type="bibr">44</xref>). In contrast, <bold>N8279</bold>-induced iCa<sup>2+</sup> potency was reduced by 6.5-fold, while full agonism was retained (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">E</italic></xref>). Furthermore, <bold>N8279</bold>-induced G&#x003b1;<sub>q</sub> dissociation signaling was reduced dramatically such that the C/R curve did not saturate, supporting that the <bold>N8279</bold> potency is blunted by &#x0003e;20-fold and the maximal efficacy decreased by &#x0223c;45% (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">F</italic></xref>). The effect magnitude discrepancy between measurements of iCa<sup>2+</sup> and G&#x003b1; dissociation likely reflects signal amplification differences between the assays. <bold>N8279</bold>-induced &#x003b2;arr2 recruitment potency at GHSR<sub>1a</sub><sup>A204E</sup> was similarly diminished (&#x0003e;20-fold) and did not reach saturation, with a maximal efficacy comparable to ghrelin (&#x0223c;35%; <xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">G</italic></xref>). Thus, relative to ghrelin, <bold>N8279</bold> signaling requires distinct ECL2 sites and/or ECD-dependent conformational states.</p><p>Next, we used the NMR-based homology model of the ghrelin-bound GHSR<sub>1a</sub> (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S3<italic toggle="yes">G</italic></ext-link>) (<xref rid="r30" ref-type="bibr">30</xref>) to simulate <bold>N8279</bold>-GHSR<sub>1a</sub> binding. We deprioritized the antagonist-bound GHSR<sub>1a</sub> crystal structure (<xref rid="r45" ref-type="bibr">45</xref>) (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">H</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S7</ext-link>) because it better models the inactive GHSR<sub>1a</sub> conformation (<xref rid="r45" ref-type="bibr">45</xref>). Docking <bold>N8279</bold> with ghrelin removed discloses two potential binding modes for <bold>N8279</bold> within the apo-GHSR<sub>1a</sub> (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">I</italic></xref>). Both modes display strong ionic interactions between <bold>N8279</bold>&#x02019;s propylamine moiety and specific acidic (negatively charged) GHSR<sub>1a</sub> residues. In one mode (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">J</italic></xref>, red), <bold>N8279</bold>'s terminal tertiary amine group forms a salt bridge with the conserved TMIII residue Glu124, located within the deep transmembrane pocket (GHSR<sub>1a</sub><sup>DTP</sup>). In the second mode (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">K</italic></xref>, blue), <bold>N8279</bold>'s propylamine moiety forms a salt bridge with Asp99 toward the top of TMII, enabling an extended binding mode into the ECD (GHSR<sub>1a</sub><sup>ECD</sup>) or extracellular vestibule, including the extracellular end of TMVII and ECL2. Notably, the superficial residue Asp99 is too distant from Glu124 (12.7 &#x000c5;) for <bold>N8279</bold> to interact with both sites simultaneously (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">I</italic></xref>). Thus, both docking models suggest that <bold>N8279</bold> binds GHSR<sub>1a</sub> via ionic interactions with spatially distinct anchor residues. In GHSR<sub>1a</sub><sup>ECD</sup>, <bold>N8279</bold>&#x02019;s methoxy-aromatic and amide moieties form hydrogen bonds with or adjacent to potential allosteric sites based on prior mutagenesis by others (<xref rid="r44" ref-type="bibr">44</xref>, <xref rid="r46" ref-type="bibr">46</xref>), including Asn305 on TMVII and Glu197, Arg199, or Pro200 in ECL2 (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">K</italic></xref>). Here, <bold>N8279</bold>&#x02019;s amide group forms an H<sup>+</sup> bond with Cys198, a highly conserved GPCR residue that constrains ECL2 flexibility (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">K</italic></xref>) (<xref rid="r47" ref-type="bibr">47</xref>). Notably, <bold>N8279</bold> had comparable docking scores within both potential binding pockets: GHSR<sub>1a</sub><sup>ECD</sup> (&#x02212;6.732) and GHSR<sub>1a</sub><sup>DTP</sup> (&#x02212;6.767) (<xref rid="fig03" ref-type="fig">Fig. 3 <italic toggle="yes">J</italic> and <italic toggle="yes">K</italic></xref>).</p><p>To test our model, we made point mutations to predicted <bold>N8279</bold>-GHSR<sub>1a</sub> interaction sites or residue clusters (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">L</italic></xref>). Given the evidence for critical ECL2-dependent contributions to <bold>N8279</bold> signaling (<xref rid="fig03" ref-type="fig">Fig. 3 <italic toggle="yes">E</italic>&#x02013;<italic toggle="yes">G</italic></xref>), as well as the absolute requirement of the GHSR<sub>1a</sub><sup>DTP</sup> anchor residue, Glu124, for GHSR<sub>1a</sub> function/activation (<xref rid="r30" ref-type="bibr">30</xref>, <xref rid="r45" ref-type="bibr">45</xref>, <xref rid="r46" ref-type="bibr">46</xref>), we prioritized the GHSR<sub>1a</sub><sup>ECD</sup>-<bold>N8279</bold> docking model for mutagenesis. Alanine substitution to the putative anchor residue Asp99 (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">K</italic></xref>, blue) abolished <bold>N8279</bold> signaling (<xref rid="fig03" ref-type="fig">Fig. 3 <italic toggle="yes">M</italic> and <italic toggle="yes">N</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S6 <italic toggle="yes">B</italic> and <italic toggle="yes">C</italic></ext-link>). However, the surface expression of this was reduced markedly (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S6<italic toggle="yes">A</italic></ext-link>), as shown previously (<xref rid="r45" ref-type="bibr">45</xref>). Mutations were not made to Cys198<sup>ECL2</sup> (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">K</italic></xref>, light blue) because it precludes GPCR stability and ligand binding (<xref rid="r48" ref-type="bibr">48</xref>). Instead, we made alanine substitutions to three adjacent, putative allosteric (<xref rid="r44" ref-type="bibr">44</xref>, <xref rid="r46" ref-type="bibr">46</xref>) and/or structurally integral (<xref rid="r30" ref-type="bibr">30</xref>) ECL2 residues: Glu197, Arg199, and Pro200 (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">K</italic></xref>, blue). We also made an alanine substitution to Asn305, which is located at the extracellular end of TMVII (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">K</italic></xref>, blue) and thus is considered within the ECD.</p><p>Relative to the WT receptor, the surface expression of the GHSR<sub>1a</sub><sup>E197A</sup> was reduced moderately, the GHSR<sub>1a</sub><sup>R199A</sup> was comparable, and the GHSR<sub>1a</sub><sup>P200A</sup> was increased mildly (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S6<italic toggle="yes">A</italic></ext-link>). <bold>N8279</bold> potency at the GHSR<sub>1a</sub><sup>E197A</sup> was diminished by &#x0223c;3- to 10-fold in iCa<sup>2+</sup> and G&#x003b1;<sub>q</sub> dissociation, respectively, whereas the <bold>N8279</bold> E<sub>max</sub> was reduced in iCa<sup>2+</sup>, but not G&#x003b1;<sub>q</sub> dissociation assays (<xref rid="fig03" ref-type="fig">Fig. 3 <italic toggle="yes">M</italic> and <italic toggle="yes">N</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S6 <italic toggle="yes">B</italic> and <italic toggle="yes">C</italic></ext-link>). The GHSR<sub>1a</sub><sup>R199A</sup> mutation did not affect <bold>N8279</bold> potency in either assay, but its E<sub>max</sub> was reduced mildly in iCa<sup>2+</sup> assays (<xref rid="fig03" ref-type="fig">Fig. 3 <italic toggle="yes">M</italic> and <italic toggle="yes">N</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S6 <italic toggle="yes">B</italic> and <italic toggle="yes">C</italic></ext-link>). <bold>N8279</bold> potency and E<sub>max</sub> were reduced dramatically at the GHSR<sub>1a</sub><sup>P200A</sup> in both G&#x003b1;<sub>q</sub> dissociation and iCa<sup>2+</sup> assays (<xref rid="fig03" ref-type="fig">Fig. 3 <italic toggle="yes">M</italic> and <italic toggle="yes">N</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S6 <italic toggle="yes">B</italic> and <italic toggle="yes">C</italic></ext-link>). Grouped analysis of the <bold>N8279</bold> potency and E<sub>max</sub> at GHSR<sub>1a</sub><sup>A204E</sup> relative to other mutants supported markedly decreased <bold>N8279</bold>-induced G&#x003b1;<sub>q</sub> signaling at this ECL2 residue (<xref rid="fig03" ref-type="fig">Fig. 3 <italic toggle="yes">E</italic>, <italic toggle="yes">F</italic>, <italic toggle="yes">M</italic>, and <italic toggle="yes">N</italic></xref>), despite its location being outside of the putative GHSR<sub>1a</sub><sup>ECD</sup> binding pocket (<xref rid="fig03" ref-type="fig">Fig. 3 <italic toggle="yes">A</italic> and <italic toggle="yes">K</italic></xref>). Alanine substitution to Asn305 did not affect surface expression relative to the WT receptor (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S6<italic toggle="yes">A</italic></ext-link>), although <bold>N8279</bold>-G&#x003b1;<sub>q</sub> dissociation was reduced dramatically and <bold>N8279</bold>-iCa<sup>2+</sup> potency was reduced moderately (6.5-fold). Surprisingly, the <bold>N8279</bold>-iCa<sup>2+</sup> E<sub>max</sub> was elevated at GHSR<sub>1a</sub><sup>N305A</sup> (<xref rid="fig03" ref-type="fig">Fig. 3 <italic toggle="yes">M</italic> and <italic toggle="yes">N</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S6 <italic toggle="yes">B</italic> and <italic toggle="yes">C</italic></ext-link>). Generally, any observed differences between <bold>N8279</bold>-induced G&#x003b1;<sub>q</sub> dissociation or iCa<sup>2+</sup> at these mutants could be due to distinctions in assay kinetics or signal amplification, GPCR-transducer expression ratios, and/or the involvement of other transducers (e.g., G&#x003b1;<sub>11</sub>, G&#x003b1;<sub>i/o</sub>, G&#x003b2;&#x003b3;) in the iCa<sup>2+</sup> response (<xref rid="r49" ref-type="bibr">49</xref>, <xref rid="r50" ref-type="bibr">50</xref>). Together, these mutagenesis findings support that <bold>N8279</bold> signaling requires GHSR<sub>1a</sub> sites within and/or conformational states determined by the ECD, especially in ECL2.</p><p>For comparison, we evaluated ghrelin-stimulated G&#x003b1;<sub>q</sub> dissociation and iCa<sup>2+</sup> at each GHSR<sub>1a</sub><sup>ECD</sup> mutant. Ghrelin signaling was reduced markedly at GHSR<sub>1a</sub><sup>D99A</sup> in both assays (<xref rid="fig03" ref-type="fig">Fig. 3 <italic toggle="yes">M</italic> and <italic toggle="yes">N</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S6 <italic toggle="yes">D</italic> and <italic toggle="yes">E</italic></ext-link>), supporting previous findings (<xref rid="r45" ref-type="bibr">45</xref>). However, ghrelin potency at the GHSR<sub>1a</sub><sup>D99A</sup> was similar to GHSR<sub>1a</sub><sup>WT</sup> in G&#x003b1;<sub>q</sub> dissociation assays (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">M</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S6<italic toggle="yes">D</italic></ext-link>). Mutations to Glu197, Arg199, or Pro200 did not significantly affect ghrelin-stimulated G&#x003b1;<sub>q</sub> dissociation or iCa<sup>2+</sup> potency (<xref rid="fig03" ref-type="fig">Fig. 3 <italic toggle="yes">M</italic> and <italic toggle="yes">N</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S6 <italic toggle="yes">D</italic> and <italic toggle="yes">E</italic></ext-link>), consistent with prior findings (<xref rid="r44" ref-type="bibr">44</xref>, <xref rid="r46" ref-type="bibr">46</xref>). Ghrelin&#x02019;s E<sub>max</sub> was unaffected at GHSR<sub>1a</sub><sup>R199A</sup> and GHSR<sub>1a</sub><sup>P200A</sup>, but it was reduced moderately at GHSR<sub>1a</sub><sup>E197A</sup> in iCa<sup>2+</sup> assays (<xref rid="fig03" ref-type="fig">Fig. 3 <italic toggle="yes">M</italic> and <italic toggle="yes">N</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S6 <italic toggle="yes">D</italic> and <italic toggle="yes">E</italic></ext-link>), consistent with its reduced expression (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S6<italic toggle="yes">A</italic></ext-link>). Furthermore, grouped analyses (derived from <xref rid="fig03" ref-type="fig">Fig. 3 <italic toggle="yes">B</italic> and <italic toggle="yes">C</italic></xref>) supported that ghrelin potency is unaffected at the GHSR<sub>1a</sub><sup>A204E</sup> mutant and its E<sub>max</sub> is decreased only in G&#x003b1;<sub>q</sub> dissociation assays (<xref rid="fig03" ref-type="fig">Fig. 3 <italic toggle="yes">M</italic> and <italic toggle="yes">N</italic></xref>), consistent with reduced expression of this mutant (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S6<italic toggle="yes">A</italic></ext-link>). Ghrelin-G&#x003b1;<sub>q</sub> dissociation potency was reduced at GHSR<sub>1a</sub><sup>N305A</sup>, albeit to a much lesser extent than <bold>N8279</bold> (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">M</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S6 <italic toggle="yes">B</italic> and <italic toggle="yes">D</italic></ext-link>). Nonetheless, ghrelin-iCa<sup>2+</sup> potency was not significantly affected by the N305A mutation (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">N</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S6<italic toggle="yes">E</italic></ext-link>). The ghrelin E<sub>max</sub> at GHSR<sub>1a</sub><sup>N305A</sup> was increased in both assays (<xref rid="fig03" ref-type="fig">Fig. 3 <italic toggle="yes">M</italic> and <italic toggle="yes">N</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S6 <italic toggle="yes">D</italic> and <italic toggle="yes">E</italic></ext-link>), similar to that seen for <bold>N8279</bold>-induced iCa<sup>2+</sup> (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">N</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S6<italic toggle="yes">C</italic></ext-link>). Collectively, these findings demonstrate that Glu197, Pro200, Ala204, and, in part, Asn305 are critical and specific GHSR<sub>1a</sub><sup>ECD</sup> sites for <bold>N8279</bold> relative to ghrelin.</p><p>Collectively, the data in <xref rid="fig03" ref-type="fig">Fig. 3</xref> support that <bold>N8279</bold> signaling requires molecular determinants within GHSR<sub>1a</sub><sup>ECD</sup> and particularly ECL2. All pharmacological results and statistical comparisons for <xref rid="fig01" ref-type="fig">Fig. 1</xref> are shown in <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Table S5</ext-link>.</p></sec><sec id="s8"><title>N8279 Is Brain-Penetrant and Attenuates DA-Driven Behavior.</title><p>Pharmacokinetic studies with intravenous (IV; 1 mg/kg), oral gavage (PO; 5 mg/kg), and intraperitoneal (IP; 5 mg/kg) administration in C57BL/6 mice reveal &#x000a0;a PO bioavailability of 7% and IP bioavailability of 27% (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S8 and Table S6</ext-link>). Significantly, IP administration of <bold>N8279</bold> (5 mg/kg) delivered pharmacologically relevant levels (&#x0223c;200 nM) in brain within 15 min, reaching peak concentrations (C<sub>max</sub>) of 259 nM at 2 h, followed by a slow decline and elimination by 24 h (<xref rid="fig04" ref-type="fig">Fig. 4<italic toggle="yes">A</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S8 and Table S6</ext-link>). In the brain, <bold>N8279</bold> has a half-life (<italic toggle="yes">t</italic><sub>1/2</sub>) of 6.6 to 11 h after IP and PO administration, maintaining levels above its G&#x003b1;<sub>q</sub>/iCa<sup>2+</sup> EC<sub>50</sub> (&#x0223c;35 nM, <xref rid="fig01" ref-type="fig">Fig. 1 <italic toggle="yes">F</italic> and <italic toggle="yes">H</italic></xref>) for an extended period (&#x0003e;7 h) with a brain/plasma ratio for <bold>N8279</bold> (IP) in the range of 0.6 to 0.9:1 (<xref rid="fig04" ref-type="fig">Fig. 4<italic toggle="yes">A</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S8 and Table S6</ext-link>). In summary, <bold>N8279</bold> achieves rapid, sustained, and pharmacologically relevant concentrations in mouse brain following systemic administration.</p><fig position="float" id="fig04" fig-type="figure"><label>Fig. 4.</label><caption><p><bold>N8279</bold> is brain-penetrant and attenuates aberrant DAergic behavior in mice. (<italic toggle="yes">A</italic>) Analysis of brain (red) and plasma [<bold>N8279</bold>] (orange) over 24 h in C57BL/6 mice treated with <bold>N8279</bold> (5 mg/kg, IP). <bold>N8279</bold> C<sub>max</sub> at &#x0223c;2 h = 123 ng/mL (259 nM). <bold>N8279</bold> (IP) brain half-life (t<sub>1/2</sub>) = 6.6 h, plasma t<sub>1/2</sub> = 3.8 h. (<italic toggle="yes">B</italic>) Spontaneous hyperlocomotion in DAT KO mice. 30 min (gray box) acclimation prior to injection (black arrow) of <bold>N8279</bold> (2.5, 5, or 10 mg/kg, IP) or vehicle (5% DMSO, saline). Horizontal locomotion was monitored for 120 min postinjection, and beam breaks were collected in 5 min bins. Results are presented as mean &#x000b1; SEM. <bold>N8279</bold>-treated DAT KO mice had reduced locomotion relative to vehicle-treated controls. Postinjection, repeated measures ANOVA (RMANOVA), time: [<italic toggle="yes">F</italic>(7.6,411.8) = 14.7, <italic toggle="yes">P</italic> &#x0003c; 0.0001], dose: [<italic toggle="yes">F</italic>(3,54) = 3.4, <italic toggle="yes">P</italic> = 0.022], time &#x000d7; dose interaction: [<italic toggle="yes">F</italic>(69,1242) = 1.2, <italic toggle="yes">P</italic> = 0.118]. No baseline differences were detected between groups. Baseline RMANOVA, time: [<italic toggle="yes">F</italic>(2.4,131.0) = 3.0, <italic toggle="yes">P</italic> = 0.039], dose: [<italic toggle="yes">F</italic>(3,54) = 0.06, <italic toggle="yes">P</italic> = 0.979], time &#x000d7; dose interaction: [<italic toggle="yes">F</italic>(15,270) = 1.4, <italic toggle="yes">P</italic> = 0.141]. <italic toggle="yes">n</italic> = 12 to 20 mice per group. (<italic toggle="yes">C</italic>) One-way ANOVA for total area under the curve (AUC, 35 to 150 min) derived from <italic toggle="yes">B</italic>. Treatment: [<italic toggle="yes">F</italic>(3,55) = 6.50, <italic toggle="yes">P</italic> = 0.0008]. Dunnett&#x02019;s multiple comparisons revealed an effect of 2.5, 5, and 10 mg/kg <bold>N8279</bold> relative to vehicle control (0 mg/kg). *<italic toggle="yes">P</italic> &#x0003c; 0.05, ***<italic toggle="yes">P</italic> &#x0003c; 0.001 versus vehicle. (<italic toggle="yes">D</italic>) Cocaine-induced behavioral sensitization in C57BL6/J mice: experimental design (<italic toggle="yes">Left</italic>) and locomotion (<italic toggle="yes">Right</italic>). Postinjection results are presented as percentage of baseline activities because locomotion was low in the <bold>N8279</bold> + vehicle group on all days. Within-group analyses (significance denoted by <sup>+</sup>) relative to day 1 showed that the vehicle + cocaine group had increased locomotion on days 2 to 5 and day 11, whereas the <bold>N8279</bold> + cocaine group had increased locomotion only on day 5. Between-group comparisons (significance denoted by *) showed that cocaine-induced sensitization was higher on day 4 and on challenge day 11 in the vehicle + cocaine compared to the <bold>N8279</bold> + cocaine group. RMANOVA: day [<italic toggle="yes">F</italic>(5,145) = 8.797, <italic toggle="yes">P</italic> &#x0003c; 0.001], treatment [<italic toggle="yes">F</italic>(2,29) = 32,523, <italic toggle="yes">P</italic> &#x0003c; 0.001], day &#x000d7; treatment [<italic toggle="yes">F</italic>(10,145) = 3.215, <italic toggle="yes">P</italic> &#x0003c; 0.001]. *<sup>/+</sup><italic toggle="yes">P</italic> &#x0003c; 0.05, ***<sup>/+++</sup><italic toggle="yes">P</italic> &#x0003c; 0.001. <italic toggle="yes">n</italic> = 9 to 12 mice/group.</p></caption><graphic xlink:href="pnas.2112397119fig04" position="float"/></fig><p>To evaluate the effect of <bold>N8279</bold> on DA-modulated behavior in&#x000a0;vivo, we first used DAT KO mice, which have constitutively elevated extracellular DA levels and consequently spontaneous hyperactivity in a novel open field (<xref rid="r51" ref-type="bibr">51</xref>). After a 30-min acclimation period, male and female DAT KO mice were administered vehicle or pharmacologically relevant, brain-penetrant doses of <bold>N8279</bold> (<xref rid="fig04" ref-type="fig">Fig. 4<italic toggle="yes">A</italic></xref>; 2.5, 5, or 10 mg/kg, IP), and returned to the open field with locomotion monitored for an additional 120 min. Each dose of <bold>N8279</bold> reduced overall hyperlocomotion in DAT KO mice relative to vehicle controls (<xref rid="fig04" ref-type="fig">Fig. 4 <italic toggle="yes">B</italic> and <italic toggle="yes">C</italic></xref>). Parallel control experiments with inbred male and female C57BL/6J mice indicated that <bold>N8279</bold> does not affect novelty-induced open-field locomotion (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S9</ext-link>).</p><p>We next assessed cocaine-induced behavioral sensitization in male and female C57BL/6J mice following subchronic (8-d) administration of the vehicle or <bold>N8279</bold> (5 mg/kg, IP) in the home cage. Subsequently, mice were given the same treatments, and this was followed with injection (IP) of vehicle or cocaine (20 mg/kg) in the open field once a day for 5 consecutive days (<xref rid="fig04" ref-type="fig">Fig. 4 <italic toggle="yes">D</italic></xref>, <italic toggle="yes">Left</italic>). A 5-d hiatus (washout) was imposed, and behavioral sensitization was assessed the next day by giving (IP) vehicle or cocaine (challenge). The cumulative results showed that postinjection locomotor activities were low in the <bold>N8279</bold> + vehicle group and were significantly reduced from the cocaine-treated mice across all days (<xref rid="fig04" ref-type="fig">Fig. 4<italic toggle="yes">D</italic></xref>). By comparison, motor activities were stimulated acutely (day 1) to similar extents in the vehicle + cocaine and <bold>N8279</bold> + cocaine mice (<xref rid="fig04" ref-type="fig">Fig. 4 <italic toggle="yes">D</italic></xref>, <italic toggle="yes">Right</italic>). Locomotion was increased from day 1 though each day to day 5 in the vehicle + cocaine group, whereas significantly enhanced activity was observed only on day 5 in the <bold>N8279</bold> + cocaine mice. Moreover, at challenge (day 11), locomotor activity was augmented relative to day 1 in the vehicle + cocaine mice, whereby no change in activity was evident in the <bold>N8279</bold> + cocaine mice. Thus, <bold>N8279</bold> both delayed the appearance of sensitization across days and abrogated the expression of sensitization following washout (challenge, day 11).</p><p>Collectively, these results indicate that pharmacologically relevant and brain-penetrant levels of <bold>N8279</bold> ameliorate aberrant DA-mediated behavior in two mouse models of persistently disrupted DA homeostasis.</p></sec></sec><sec sec-type="discussion" id="s9"><title>Discussion</title><p content-type="flushleft">In this study, we disclose a chemotype of small molecule GHSR<sub>1a</sub> modulators with functional selectivity toward G&#x003b1;<sub>q</sub> signaling. Our results support that the lead compound from this chemical series, <bold>N8279</bold> (NCATS-SM8864), stabilizes conformational states that drive the apo- and ghrelin-bound GHSR<sub>1a</sub> toward G&#x003b1;<sub>q</sub> coupling over other G proteins and &#x003b2;arr-dependent cellular responses. Importantly, <bold>N8279</bold> has excellent brain penetrance and exhibits salutary effects on DA-induced behavior in both genetic and pharmacological mouse models of disrupted DA homeostasis.</p><p>Collectively, our findings indicate that <bold>N8279</bold>-induced GHSR<sub>1a</sub> signaling originates, at least in part, from an extended binding mode into the extracellular vestibule and/or conformational constraints imposed by the GHSR<sub>1a</sub><sup>ECD</sup>, especially ECL2. This notion is supported most strongly by significantly reduced <bold>N8279</bold> potency upon mutation of specific ECL2 residues, including Ala204, Pro200, and to a lesser extent Glu197. Critically, these effects are distinct from the endogenous GHSR<sub>1a</sub> ligand, ghrelin. Although <bold>N8279</bold> is not predicted to interact directly with these residues in our in silico models, they are adjacent or proximal to predicted interaction sites within our GHSR<sub>1a</sub><sup>ECD</sup> binding pocket model. Thus, these mutations may result in GHSR<sub>1a</sub> conformation(s) that are less accessible for <bold>N8279</bold> binding and/or less capable of stabilizing a signaling-competent <bold>N8279</bold>-GHSR<sub>1a</sub> complex via perturbation of the ECD structure and/or local disruption(s) to proximal interaction sites. Together, these findings suggest that <bold>N8279</bold> signaling at the apo-GHSR<sub>1a</sub> is most likely mediated by a bitopic, extended binding mode that is conformationally dependent upon the GHSR<sub>1a</sub><sup>ECD</sup>. Additionally, <bold>N8279</bold>-GHSR<sub>1a</sub><sup>ECD</sup> interaction(s) may be state dependent, given that concomitant docking of <bold>N8279</bold> and ghrelin peptide (1&#x02013;17, amino acids) (<xref rid="r30" ref-type="bibr">30</xref>) predicts a strong ionic interaction of <bold>N8279</bold> with ECL2 when at the ghrelin-occupied GHSR<sub>1a</sub> (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S3<italic toggle="yes">G</italic></ext-link>). Pharmacologically, these binding properties may contribute to <bold>N8279</bold>&#x02019;s ability to modestly enhance, or at least noncompetitively retain, G&#x003b1;<sub>q</sub> signaling efficacy at the ghrelin-bound GHSR<sub>1a</sub> (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">G</italic></xref>; <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S3<italic toggle="yes">F</italic></ext-link>). Alternatively, these effects could arise from asymmetric interactions between ghrelin, <bold>N8279</bold>, and GHSR<sub>1a</sub> homodimers within allosteric and/or orthosteric binding pockets. This notion is consistent with ghrelin- and <bold>N8279</bold>-induced iCa<sup>2+</sup> exhibiting an <italic toggle="yes">h</italic> &#x0003e; 1 at the apo-GHSR<sub>1a</sub> (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">E</italic></xref>) and <bold>N8279</bold> having an <italic toggle="yes">h</italic> of unity at the orthosteric agonist-bound GHSR<sub>1a</sub> (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">F</italic></xref>; <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S3<italic toggle="yes">F</italic></ext-link>). Indeed, GHSR<sub>1a</sub> homodimerizes (<xref rid="r52" ref-type="bibr">52</xref>) and ago-allosteric GHSR<sub>1a</sub> agonists (e.g., L-692,429) elicit similar effects to <bold>N8279</bold> via bitopic or bimodal state-dependent interaction(s) with the &#x0201c;allosteric&#x0201d; or &#x0201c;orthosteric&#x0201d; protomers of the GHSR<sub>1a</sub> dimer (<xref rid="r26" ref-type="bibr">26</xref>).</p><p>Our functional evidence supports the notion that <bold>N8279</bold> stabilizes a conformation favoring the G&#x003b1;<sub>q</sub>-bound conformation of GHSR<sub>1a</sub> over other transducers (G&#x003b1;<sub>i/o</sub>, G&#x003b1;<sub>12/13</sub>, and &#x003b2;arr2) relative to ghrelin (<xref rid="fig01" ref-type="fig">Figs. 1</xref> and <xref rid="fig02" ref-type="fig">2</xref>). Conversely, <bold>N8279</bold> displacement of ghrelin binding is blunted at the &#x003b2;arr-biased ICL2 variant, GHSR<sub>1a</sub><sup>L149G</sup>, suggesting that the &#x003b2;arr2-coupled GHSR<sub>1a</sub> renders <bold>N8279</bold> binding at the extracellular face of the receptor less accessible (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">C</italic></xref>). Thus, <bold>N8279</bold> pretreatment-induced partial GHSR<sub>1a</sub><sup>WT</sup>-&#x003b2;arr2 antagonism may depend on kinetic and/or allosteric mechanism(s). Together, these observations of bidirectional allostery are consistent with the principle of reciprocity underlying ligand&#x02013;GPCR&#x02013;transducer and allosteric coupling (i.e., ternary complex model) (<xref rid="r53" ref-type="bibr">53</xref>, <xref rid="r54" ref-type="bibr">54</xref>). Indeed, ECL2 is an established determinant of GHSR<sub>1a</sub> (<xref rid="r44" ref-type="bibr">44</xref>) and, more generally, GPCR bias (<xref rid="r55" ref-type="bibr">55</xref>, <xref rid="r56" ref-type="bibr">56</xref>). Several biased ligands elicit their effects through extended binding modes involving the cognate GPCR&#x02019;s ECD (especially ECL2), whereby superficial ligand&#x02013;receptor interactions preferentially stabilize conformations that allosterically propagate to the intracellular receptor face to influence transducer coupling and thereby functional selectivity (<xref rid="r57" ref-type="bibr">57</xref>). Some examples of these biased ligand&#x02013;GPCR pairs include the dopamine D2 receptor (D<sub>2</sub>R) (<xref rid="r55" ref-type="bibr">55</xref>), the serotonin 2B (5-HT<sub>2B</sub>R) (<xref rid="r58" ref-type="bibr">58</xref>, <xref rid="r59" ref-type="bibr">59</xref>), the muscarinic type 2 (M<sub>2</sub>R) (<xref rid="r60" ref-type="bibr">60</xref>, <xref rid="r61" ref-type="bibr">61</xref>), the &#x003b2;-adrenergic receptors (&#x003b2;<sub>1</sub>AR, &#x003b2;<sub>2</sub>AR) (<xref rid="r62" ref-type="bibr">62</xref>), and the glucagon-like peptide-1 (GLP-1) receptor (<xref rid="r63" ref-type="bibr">63</xref>). Notably, GHSR<sub>1a</sub>-containing tissues likely express different levels of signaling proteins (e.g., G&#x003b1; subunits, GRKs); thus, &#x0201c;system bias&#x0201d; (<xref rid="r64" ref-type="bibr">64</xref>, <xref rid="r65" ref-type="bibr">65</xref>) may be expected (<xref rid="fig01" ref-type="fig">Figs. 1</xref> and <xref rid="fig02" ref-type="fig">2</xref>) to play a significant role in determining <bold>N8279</bold>-induced GHSR<sub>1a</sub> functional selectivity in&#x000a0;vivo.</p><p>Pharmacokinetic studies indicate that <bold>N8279</bold> was able to sustain biologically relevant levels in brain for extended periods of time following IP administration of a low dose (5 mg/kg). Critically, in&#x000a0;vivo efficacy studies revealed that acute administration of <bold>N8279</bold> at pharmacologically relevant doses attenuated hyperlocomotion in both genetic and pharmacological models of hyperDAergia, recapitulating effects achieved by GHSR<sub>1a</sub> antagonists (<xref rid="r22" ref-type="bibr">22</xref>, <xref rid="r66" ref-type="bibr">66</xref>, <xref rid="r67" ref-type="bibr">67</xref>). Previously, we reported that the antagonist YIL781 reduced hyperlocomotion in cocaine-sensitized WT but not DA neuron&#x02013;specific &#x003b2;arr2 KO mice (<xref rid="r22" ref-type="bibr">22</xref>), suggesting that &#x003b2;arr2 inhibition was required for GHSR<sub>1a</sub> antagonists to blunt cocaine-induced neuroadaptations. Additionally, GHSR<sub>1a</sub>-induced &#x003b2;arr signaling and, more generally, G&#x003b1;<sub>12/13</sub> signaling (<xref rid="r68" ref-type="bibr">68</xref>, <xref rid="r69" ref-type="bibr">69</xref>) are required for RhoA-dependent actin remodeling&#x02014;a process integral to neuroplasticity in DA neurons (<xref rid="r70" ref-type="bibr">70</xref>, <xref rid="r71" ref-type="bibr">71</xref>). Together, these prior findings suggest that &#x003b2;arr2 might be necessary for the proaddictive effects of GHSR<sub>1a</sub> activation, particularly during DA plasticity&#x02013;dependent reward learning (e.g., behavioral sensitization). Here, we show that <bold>N8279</bold> reduced novelty-related hyperlocomotion in DAT KO but not in inbred C57BL6/J mice (<xref rid="fig03" ref-type="fig">Fig. 3 <italic toggle="yes">B</italic> and <italic toggle="yes">C</italic></xref>) and depressed behavioral sensitization in cocaine-sensitized C57BL/6J mice. Thus, it appears that reductions in GHSR<sub>1a</sub>-&#x003b2;arr2 signaling may preferentially blunt the development and/or expression of behaviors mediated by sensitized neurocircuits (e.g., mesolimbic, nigrostriatal) that have undergone DA-dependent plasticity, whereas GHSR<sub>1a</sub> regulation of metabolic homeostasis (e.g., feeding, glucose/insulin homeostasis, growth hormone secretion) and DA cell neuroprotection are generally considered G protein mediated (<xref rid="r9" ref-type="bibr">9</xref>, <xref rid="r23" ref-type="bibr">23</xref>, <xref rid="r72" ref-type="bibr">72</xref>, <xref rid="r73" ref-type="bibr">73</xref>). Thus, an agonist functionally selective for G&#x003b1;<sub>q</sub> should bias GHSR<sub>1a</sub> away from &#x003b2;arr or alternative G&#x003b1; signaling and thus may retain the antiaddictive effects of GHSR<sub>1a</sub> antagonists while preserving, normalizing, or augmenting G&#x003b1;<sub>q</sub>-dependent endocrine homeostatic and/or neuroprotective GHSR<sub>1a</sub> functions. Moreover, reductions in GHSR<sub>1a</sub>-mediated &#x003b2;arr signaling (e.g., desensitization, down-regulation) by a G protein&#x02013;biased agonist should, in principle, minimize tolerance and retain therapeutic efficacy with chronic administration.</p><p>To elucidate these hypotheses adequately, future studies will require the development of additional pharmacological tools with distinct signaling properties and, ideally, transgenic animal models that recapitulate both pathway-selective and complete bias in&#x000a0;vivo. Fundamentally, if biased signaling can produce desired physiological outcomes with specificity, then biased ligands should provide efficacy with reduced side effects and thereby generate superior drugs. This point has significant theoretical and practical implications for the future of pharmaceutical healthcare, as described recently for the new US Food and Drug Administration (FDA)-approved opioid drug, Olinvyk (<xref rid="r74" ref-type="bibr">74</xref>, <xref rid="r75" ref-type="bibr">75</xref>). Importantly, further addressing such issues with the appropriate tools and technologies should reveal whether efficacy-based drug development strategies can be more successful than mechanism-based approaches, as suggested in recent efforts toward drug repurposing across several areas of medicine (<xref rid="r76" ref-type="bibr">76</xref><xref rid="r77" ref-type="bibr"/>&#x02013;<xref rid="r78" ref-type="bibr">78</xref>).</p><p>In summary, we present a functionally selective small molecule GHSR<sub>1a</sub> ligand that displays unique and favorable pharmacokinetics and pharmacodynamics (PK/PD). With rapidly expanding advances in molecular docking and dynamics, large-scale in silico compound library screening, and the ever-increasing availability of crystal and cryogenic electron microscopy (cryo-EM) structures, GPCR-directed drug discovery/optimization efforts have become more efficient and effective. <bold>N8279</bold> is currently an early lead candidate that can undergo further optimization within this paradigm. Nevertheless, <bold>N8279</bold> and/or its analogs may serve as an important structural scaffold for rationally designing safer and more effective GHSR<sub>1a</sub>-selective treatments to treat DAergic brain diseases, including PD, AD, and/or addictions.</p></sec><sec sec-type="materials|methods" id="s10"><title>Materials and Methods</title><sec id="s11"><title>Chemicals and Compounds.</title><p>All chemicals and reagents were purchased from MilliporeSigma or Bio-Techne Corporation, unless indicated otherwise. For details, see <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, <italic toggle="yes">SI Materials and Methods</italic></ext-link>.</p></sec><sec id="s12"><title>Animals.</title><p>All animal studies were performed in accordance with the NIH Guidelines for Animal Care and Use of Laboratory Animals and under protocols approved by the Duke University Animal Care and Use Committee (ACUC) or NIH Division of Veterinary Resources ACUC. Male C57BL/6 mice were used for pharmacokinetic studies and were purchased from Charles River Laboratories. DAT KO mice (<xref rid="r51" ref-type="bibr">51</xref>) were backcrossed for &#x0003e;10 generations onto a C57BL/6J (Jackson Laboratory) genetic background. C57BL/6J mice were used also in the novelty and behavioral sensitization experiments. Age- and sex-matched littermate mice between 2 and 6 mo of age were used for all behavioral experiments. Mice were bred and maintained on a standard 12:12 h light:dark cycle, socially housed, and supplied with standard laboratory chow and water ad libitum, except during testing.</p></sec><sec id="s13"><title>NCGC00538279 (N8279) Synthesis.</title><p>For detailed chemical synthesis procedures of <bold>N8279</bold> (NCATS-SM8864), see <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, <italic toggle="yes">SI Materials and Methods</italic></ext-link>.</p></sec><sec id="s14"><title>Cell Culture and Transfections.</title><p>U2OS, human embryonic kidney (HEK)-293/T, and HEK293/N cells were obtained from the American Type Culture Collection and cultured in Dulbecco&#x02019;s modified Eagle&#x02019;s medium supplemented with 10% (vol/vol) of fetal bovine serum and 1&#x000d7; antibiotic-antimycotic solution (100 IU-1 penicillin, 100 &#x003bc;g/mL streptomycin, and 250 ng/mL amphotericin B; MilliporeSigma). HEK293/S G&#x003b1;<sub>q/11</sub> KO and its parental WT line were characterized previously (<xref rid="r27" ref-type="bibr">27</xref>, <xref rid="r79" ref-type="bibr">79</xref>) and were a generous gift from Dr. Asuka Inoue (Tohoku University). U2OS cells stably expressing 3&#x000d7;HA-hGHSR<sub>1a</sub><sup>WT</sup> and GFP-tagged &#x003b2;arr2 and HEK293/N cells stably expressing 3&#x000d7;HA-hGHSR<sub>1a</sub><sup>WT</sup> and the luminescent Ca<sup>2+</sup> sensor mitochondrial-Aequorin (miAeq) were made by the Caron laboratory and have been described (<xref rid="r20" ref-type="bibr">20</xref>, <xref rid="r21" ref-type="bibr">21</xref>). All cell lines were grown in a humidified incubator at 37&#x02009;&#x000b0;C (5% CO<sub>2</sub>). All transient transfections were performed using a standard calcium phosphate method.</p></sec><sec id="s15"><title>Plasmids.</title><p>All plasmid constructs were purchased commercially or received as a generous gift from collaborative investigators. For details on plasmid acquisition and cloning procedures, see <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, <italic toggle="yes">SI Materials and Methods</italic></ext-link>. Mutagenesis was performed with the QuikChange site-directed mutagenesis kit (Agilent Technologies, Santa Clara, CA).</p></sec><sec id="s16"><title>High-Throughput and Directed Library Compound Screening.</title><sec id="s17"><title>Quantitative high-throughput screening.</title><p>Quantitative high-throughput screening (qHTS) was performed against &#x0223c;47,000 compounds from the Sytravon library and the NPC using the PathHunter U2OS GHSR<sub>1a</sub>-&#x003b2;arr1 cells and the &#x003b2;arr Assay Kit (DiscoverX). Prior to the screening, the assay was miniaturized to a 1,536-well format and optimized in terms of signal-to-background window (S/B), Z factor, and potency of ghrelin control. The initial assay validation was performed with Library of Pharmacologically Active Compounds (Sigma-Aldrich) to confirm plate-to-plate reproducibility of parameters, hit rate identification, etc. For qHTS, two doses of the compounds&#x02014;11 and 57 &#x003bc;M&#x02014;were used to measure GHSR<sub>1a</sub> activation using a fully automated robotic screening system (Kalypsys). Briefly, 1.2 &#x000d7; 10<sup>3</sup> cells were seeded with MultiDrop Combi dispenser (Thermo Fisher Scientific) into white solid-bottom tissue culture&#x02013;treated 1,536-well plates (Aurora Microplates) in 3 &#x003bc;L of AssayComplete Cell Plating 5 Reagent (DiscoverX) and cultured overnight. Next, 1 &#x003bc;L per well of 1 &#x003bc;M ghrelin diluted in Hanks' balanced salt solution (HBSS) + 10 mM Hepes (HH buffer) was added to one column of the plate, while all other wells were dispensed with 1 &#x003bc;L per well of HH buffer for matching the assay conditions. Subsequently, the libraries&#x02019; compounds in DMSO solution were transferred from the source plates to the assay plates at 23 nL per well. The plates were incubated for 90 min, followed by addition of 1.5 &#x003bc;L per well PathHunter Detection Reagent prepared according to the manufacturer&#x02019;s instructions. After 60 min of incubation at ambient temperature, the luminescent signal was measured on a ViewLux uHTS Microplate Imager (Perkin-Elmer) with 20 s exposure. Quality of the screening was evaluated based on the median characteristics of Z factor and S/B, which were 0.53 and &#x0223c;4.5-fold, respectively. Hit detection window parameters were calculated based on results obtained from the vehicle control (EC<sub>0</sub>) and ghrelin as the positive control (EC<sub>100</sub> = 250 nM final concentration) conditions. A cutoff of &#x0003e;60% activation by either the lower or higher compound&#x02019;s dose was used to select primary hits. A follow-up PathHunter U2OS GHSR<sub>1a</sub> &#x003b2;arr1 assay was performed on 145 selected primary compounds. They were retested at seven doses in the range [57 &#x003bc;M to 3.7 nM], applying the same protocol as for qHTS. Thirty-six hits were selected based on curve response class 1, 2, or 3 for further validation.</p></sec></sec><sec id="s18"><title>X-Ray Diffraction.</title><p>Single crystal X-ray diffraction studies were conducted on a Bruker Kappa Photon II CPAD diffractometer equipped with Cu K<sub>&#x003b1;</sub> radiation (&#x003bb; = 1.54178 &#x000c5;). Crystals of the subject compound were grown by dissolving &#x0223c;1 mg of sample in 350 &#x003bc;L of 90:10 dichloroethane/methanol solution, which was then vapor diffused with Pentane over several days. A 0.267 &#x000d7; 0.243 &#x000d7; 0.228 mm piece of a colorless block was mounted on a Cryoloop with Paratone oil. Data were collected in a nitrogen gas stream at 285 K using &#x003d5; and &#x003d6; scans. The crystal-to-detector distance was 40 mm using variable exposure time (20 to 90s) depending on &#x003b8; with a scan width of 2.0&#x000b0;. Data collection was 99.5% complete to 59.009&#x000b0; in &#x003b8; (0.90 &#x000c5;). A total of 58,959 reflections were collected, covering the indices &#x02212;17 &#x02264; <italic toggle="yes">h</italic> &#x02264; 17, &#x02212;16 &#x02264; k &#x02264; 16, and &#x02212;24 &#x02264; l &#x02264; 24. A total of 6,947 reflections were found to be symmetry independent, with an R<sub>int</sub> of 0.0596. Indexing and unit cell refinement indicated a primitive, monoclinic lattice. The space group was found to be <italic toggle="yes">P</italic>2<sub>1</sub>/c. The data were integrated using the Bruker SAINT software program and scaled using the SADABS software program. Solution by direct methods (SHELXT) produced a complete phasing model for refinement. All nonhydrogen atoms were refined anisotropically by full-matrix least-squares (SHELXL-2014). All carbon bonded hydrogen atoms were placed using a riding model. Their positions were constrained relative to their parent atom using the appropriate HFIX command in SHELXL-2014. All other hydrogen atoms (H-bonding) were located in the difference map. Their relative positions were restrained using DFIX commands and their thermals freely refined. Crystallographic data are summarized in <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Table S2</ext-link>.</p></sec><sec id="s19"><title>GHSR<sub>1a</sub> Radioligand Binding Assays.</title><p>[<sup>125</sup>I]ghrelin-GHSR<sub>1a</sub> binding assays were performed as described (<xref rid="r45" ref-type="bibr">45</xref>), with modifications outlined in <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, <italic toggle="yes">SI Materials and Methods</italic></ext-link>.</p></sec><sec id="s20"><title>G&#x003b1;<sub>q</sub>-Dependent Intracellular Ca<sup>2+</sup> Mobilization.</title><p>iCa<sup>2+</sup> assays were performed as described (<xref rid="r21" ref-type="bibr">21</xref>), with modifications described in <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, <italic toggle="yes">SI Materials and Methods</italic></ext-link>.</p></sec><sec id="s21"><title>&#x003b2;arr2<sup>GFP</sup> Translocation.</title><p>&#x003b2;arr2<sup>GFP</sup> translocation assays were performed as described (<xref rid="r20" ref-type="bibr">20</xref>), with modifications described in <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, <italic toggle="yes">SI Materials and Methods</italic></ext-link>.</p></sec><sec id="s22"><title>NanoBiT-Based G&#x003b1;<sub>q</sub> Dissociation and &#x003b2;arr2 Recruitment Assays.</title><p>G&#x003b1;<sub>q</sub><sup>LgBiT</sup> dissociation assays were performed as described (<xref rid="r32" ref-type="bibr">32</xref>), with modifications described in <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, <italic toggle="yes">SI Materials and Methods</italic></ext-link>. <sup>SmBiT</sup>&#x003b2;arr2 recruitment assays were performed using a modified &#x003b2;arr2 recruitment protocol as described previously (<xref rid="r27" ref-type="bibr">27</xref>). Detailed procedures for both NanoBiT assays are described in the <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, <italic toggle="yes">SI Materials and Methods</italic></ext-link>.</p></sec><sec id="s23"><title>BRET-Based G&#x003b1;<sub>q</sub> Dissociation and &#x003b2;arr2 Recruitment Assays.</title><p>G&#x003b1;<sup>RLuc8</sup>-G&#x003b3;<sup>GFP2</sup> dissociation assays (TRUPATH) were performed as originally described (<xref rid="r33" ref-type="bibr">33</xref>). GHSR<sub>1a</sub><sup>WT-RLucII</sup> and GHSR<sub>1a</sub><sup>L149G-RLucII</sup>-<sup>Venus</sup>&#x003b2;arr2 recruitment assays were performed as described previously (<xref rid="r21" ref-type="bibr">21</xref>). Detailed procedures for both BRET assays are described in the <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, <italic toggle="yes">SI Materials and Methods</italic></ext-link>.</p></sec><sec id="s24"><title>Chemiluminescent Fixed-Cell ELISA.</title><p>Quantitative, fixed-cell ELISAs were performed as described (<xref rid="r80" ref-type="bibr">80</xref>), but with modification for chemiluminescent detection of surface-expressed GHSR<sub>1a</sub>. A detailed procedure can be found in the <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, <italic toggle="yes">SI Materials and Methods</italic></ext-link>.</p></sec><sec id="s25"><title>Bystander BRET.</title><p>MyrPalm<sup>Venus</sup> and 2&#x000d7;FYVE<sup>Venus</sup> bBRET assays were performed as described (<xref rid="r38" ref-type="bibr">38</xref>, <xref rid="r40" ref-type="bibr">40</xref>), with modifications described in <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, <italic toggle="yes">SI Materials and Methods</italic></ext-link>.</p></sec><sec id="s26"><title>SRF-RE Transcriptional Activity.</title><p>SRF-RE transcriptional activation assays were performed as described (<xref rid="r20" ref-type="bibr">20</xref>), with modifications described in <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, <italic toggle="yes">SI Materials and Methods</italic></ext-link>.</p></sec><sec id="s27"><title>Molecular Docking.</title><p>Molecular docking studies were performed using the Glide and Maestro user interface (Release 2019&#x02013;4, Schrodinger LLC) as described (<xref rid="r81" ref-type="bibr">81</xref>, <xref rid="r82" ref-type="bibr">82</xref>). The model structure of ghrelin-bound GHSR<sub>1a</sub> (<xref rid="r30" ref-type="bibr">30</xref>) and the X-ray crystal structure of antagonist-bound GHSR<sub>1a</sub> (<xref rid="r45" ref-type="bibr">45</xref>) were used to represent the active and inactive state of GHSR<sub>1a</sub>, respectively. The Protein Preparation Wizard function was used to assign bond orders, add hydrogen atoms, and remove water molecules that did not participate in interactions. The GHSR<sub>1a</sub> models were subjected to energy minimization using the OPLS3 algorithm (A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins). A receptor grid box of 30 &#x000d7; 30 &#x000d7; 30 &#x000c5;<sup>3</sup> with a default inner box (10 &#x000d7; 10 &#x000d7; 10 &#x000c5;<sup>3</sup>) was centered on the ligand binding pocket. The ligand structures were generated and prepared using the LigPrep function with the OPLS3 force field. Flexible ligand docking was performed using the &#x0201c;standard precision&#x0201d; Glide algorithm, and after the postdocking minimization, the pose with the best docking score was evaluated.</p></sec><sec id="s28"><title>Pharmacokinetic Analysis.</title><p>Male C57BL/6 mice (<italic toggle="yes">n</italic> = 3/time point) were administered <bold>N8279</bold> at 1 mg/kg IV, 5 mg/kg PO, and 5 mg/kg IP. Plasma, brain, and liver samples were collected over 24 h. <bold>N8279</bold> concentrations in plasma, brain, and liver homogenates were determined by LC-MS/MS. The mean concentration from three animals at each time point was used in the pharmacokinetic (PK) analysis. PK parameters were calculated with Phoenix WinNonlin Software (Ver. 8.0, Certara).</p></sec><sec id="s29"><title>Novelty-Induced Locomotor Activity in DAT KO and Inbred C57BL/6J Mice.</title><p>Open-field locomotor activity in mice was performed as described (<xref rid="r66" ref-type="bibr">66</xref>), with modifications described in <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, <italic toggle="yes">SI Materials and Methods</italic></ext-link>.</p></sec><sec id="s30"><title>Cocaine Sensitization.</title><p>Male and female C57BL6/J mice (Jackson Labs) were administered (IP) vehicle or <bold>N8279</bold> (5 mg/kg) subchronically for 8 consecutive days (once per day) (<xref rid="fig04" ref-type="fig">Fig. 4<italic toggle="yes">D</italic></xref>). Subsequently, mice were placed into the open field (Accuscan Instruments) for 30 min; they were removed, injected (IP) with vehicle or <bold>N8279</bold>, returned to the open field for 30 min, then given (IP) vehicle or cocaine (20 mg/kg) and returned to the open field for 120 min (<xref rid="fig04" ref-type="fig">Fig. 4<italic toggle="yes">D</italic></xref>). This procedure was repeated once per day for 5 consecutive days. A drug-free hiatus in the home cage was imposed for 5 d (washout), and then on day 11, the mice were challenged (IP) with vehicle or cocaine (20 mg/kg) to test for behavioral sensitization. Since the injections of vehicle and <bold>N8279</bold> occurred 30 min prior to cocaine administration, this time period was taken as baseline activity. Since this baseline locomotor activity declined across days in the <bold>N8279</bold> group, the results are presented as percent change from baseline activities.</p></sec><sec id="s31"><title>Statistics.</title><p>All data are presented as the mean &#x000b1; SEM derived from multiple independent experiments or animals. For binding and signaling assays, &#x02265;2 technical replicates were included in each experiment. These data were plotted and analyzed in GraphPad Prism version 9.0 with a statistical significance threshold defined as <italic toggle="yes">P</italic> &#x0003c; 0.05. Nonlinear regression parameters and best-fit models for all C/R data were determined statistically by an extra sum-of-squares <italic toggle="yes">F</italic>-test. The behavioral data were analyzed by the appropriate ANOVA followed by a post hoc multiple comparisons test.</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data"><label>Supplementary File</label><media xlink:href="pnas.2112397119.sapp.pdf" id="d64e4160" position="anchor"/></supplementary-material></sec></body><back><ack><p>We thank Wendy Roberts for the maintenance of the DAT KO and C57BL/6J mouse colonies (Duke University). We also thank Yushi Bai and Lauren Rochelle for performing initial GHSR<sub>1a</sub> radioligand binding and signaling assays with the hit compounds and the commercial compound library, respectively. We thank the Mouse Behavioral and Neuroendocrine Analysis Core Facility staff for running the behavioral sensitization experiments, with Dr. Ramona M. Rodriguiz statistically analyzing these data (Duke University). Some of the equipment and software used in the behavioral experiments were purchased with a grant from the North Carolina Biotechnology Center. This work has been funded by NIH grants from the National Institute on Drug Abuse, F32DA051139 (J.D.G.), U18DA052417 (L.S.B. and M.G.C.), and P30DA029925 (M.G.C., L.S.B., and K.T.); National Institute of Mental Health grant R37MH073853 (M.G.C.), and National Center for Advancing Translational Sciences grant ZIATR000083 (J.J.M.).</p></ack><fn-group><fn id="fn3" fn-type="COI-statement"><p>Competing interest statement: A provisional patent application has been deposited with the USPTO by Duke University. A decision on whether to file a formal application will be decided upon in 2022.</p></fn><fn id="fn4" fn-type="other"><p>This article is a PNAS Direct Submission.</p></fn><fn id="fn6" fn-type="supplementary-material"><p>This article contains supporting information online at <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri">https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental</ext-link>.</p></fn></fn-group><sec sec-type="data-availability" id="s32"><title>Data Availability</title><p content-type="flushleft">All study data are included in the article and/or <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2112397119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic></ext-link>.</p></sec><ref-list><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Kojima</surname></string-name>
<etal/></person-group>, <article-title>Ghrelin is a growth-hormone-releasing acylated peptide from stomach</article-title>. <source>Nature</source>
<volume>402</volume>, <fpage>656</fpage>&#x02013;<lpage>660</lpage> (<year>1999</year>).<pub-id pub-id-type="pmid">10604470</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B. K.</given-names>
<surname>Mani</surname></string-name>, <string-name><given-names>J. M.</given-names>
<surname>Zigman</surname></string-name></person-group>, <article-title>Ghrelin as a survival hormone</article-title>. <source>Trends Endocrinol. Metab.</source>
<volume>28</volume>, <fpage>843</fpage>&#x02013;<lpage>854</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">29097101</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y.</given-names>
<surname>Sun</surname></string-name>, <string-name><given-names>P.</given-names>
<surname>Wang</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Zheng</surname></string-name>, <string-name><given-names>R. G.</given-names>
<surname>Smith</surname></string-name></person-group>, <article-title>Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>101</volume>, <fpage>4679</fpage>&#x02013;<lpage>4684</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15070777</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T. D.</given-names>
<surname>M&#x000fc;ller</surname></string-name>
<etal/></person-group>, <article-title>Ghrelin</article-title>. <source>Mol. Metab.</source>
<volume>4</volume>, <fpage>437</fpage>&#x02013;<lpage>460</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26042199</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.</given-names>
<surname>Serrenho</surname></string-name>, <string-name><given-names>S. D.</given-names>
<surname>Santos</surname></string-name>, <string-name><given-names>A. L.</given-names>
<surname>Carvalho</surname></string-name></person-group>, <article-title>The role of ghrelin in regulating synaptic function and plasticity of feeding-associated circuits</article-title>. <source>Front. Cell. Neurosci.</source>
<volume>13</volume>, <fpage>205</fpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31191250</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Abizaid</surname></string-name>
<etal/></person-group>, <article-title>Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite</article-title>. <source>J. Clin. Invest.</source>
<volume>116</volume>, <fpage>3229</fpage>&#x02013;<lpage>3239</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">17060947</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y.</given-names>
<surname>Suda</surname></string-name>
<etal/></person-group>, <article-title>Down-regulation of ghrelin receptors on dopaminergic neurons in the substantia nigra contributes to Parkinson&#x02019;s disease-like motor dysfunction</article-title>. <source>Mol. Brain</source>
<volume>11</volume>, <fpage>6</fpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29458391</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>E.</given-names>
<surname>Jerlhag</surname></string-name>
<etal/></person-group>, <article-title>Ghrelin administration into tegmental areas stimulates locomotor activity and increases extracellular concentration of dopamine in the nucleus accumbens</article-title>. <source>Addict. Biol.</source>
<volume>12</volume>, <fpage>6</fpage>&#x02013;<lpage>16</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17407492</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. H.</given-names>
<surname>Morgan</surname></string-name>, <string-name><given-names>D. J.</given-names>
<surname>Rees</surname></string-name>, <string-name><given-names>Z. B.</given-names>
<surname>Andrews</surname></string-name>, <string-name><given-names>J. S.</given-names>
<surname>Davies</surname></string-name></person-group>. <article-title>Ghrelin mediated neuroprotection &#x02013; A possible therapy for Parkinson's disease?</article-title>
<source>Neuropharmacology</source>
<volume>136</volume>, <fpage>317</fpage>&#x02013;<lpage>326</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29277488</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T.</given-names>
<surname>Kienast</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Heinz</surname></string-name></person-group>, <article-title>Dopamine and the diseased brain</article-title>. <source>CNS Neurol. Disord. Drug Targets</source>
<volume>5</volume>, <fpage>109</fpage>&#x02013;<lpage>131</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16613557</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P. G.</given-names>
<surname>Strange</surname></string-name></person-group>, <article-title>Antipsychotic drugs: Importance of dopamine receptors for mechanisms of therapeutic actions and side effects</article-title>. <source>Pharmacol. Rev.</source>
<volume>53</volume>, <fpage>119</fpage>&#x02013;<lpage>133</lpage> (<year>2001</year>).<pub-id pub-id-type="pmid">11171942</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>H.</given-names>
<surname>You</surname></string-name>
<etal/></person-group>, <article-title>Molecular basis of dopamine replacement therapy and its side effects in Parkinson&#x02019;s disease</article-title>. <source>Cell Tissue Res.</source>
<volume>373</volume>, <fpage>111</fpage>&#x02013;<lpage>135</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29516217</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. R.</given-names>
<surname>Schank</surname></string-name>, <string-name><given-names>A. E.</given-names>
<surname>Ryabinin</surname></string-name>, <string-name><given-names>W. J.</given-names>
<surname>Giardino</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Ciccocioppo</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Heilig</surname></string-name></person-group>, <article-title>Stress-related neuropeptides and addictive behaviors: Beyond the usual suspects</article-title>. <source>Neuron</source>
<volume>76</volume>, <fpage>192</fpage>&#x02013;<lpage>208</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">23040815</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.</given-names>
<surname>Lindholm</surname></string-name>
<etal/></person-group>, <article-title>Current disease modifying approaches to treat Parkinson&#x02019;s disease</article-title>. <source>Cell. Mol. Life Sci.</source>
<volume>73</volume>, <fpage>1365</fpage>&#x02013;<lpage>1379</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">26616211</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names>
<surname>Yanagi</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Sato</surname></string-name>, <string-name><given-names>K.</given-names>
<surname>Kangawa</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Nakazato</surname></string-name></person-group>, <article-title>The homeostatic force of ghrelin</article-title>. <source>Cell Metab.</source>
<volume>27</volume>, <fpage>786</fpage>&#x02013;<lpage>804</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29576534</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>W. A.</given-names>
<surname>Banks</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Tsch&#x000f6;p</surname></string-name>, <string-name><given-names>S. M.</given-names>
<surname>Robinson</surname></string-name>, <string-name><given-names>M. L.</given-names>
<surname>Heiman</surname></string-name></person-group>, <article-title>Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure</article-title>. <source>J. Pharmacol. Exp. Ther.</source>
<volume>302</volume>, <fpage>822</fpage>&#x02013;<lpage>827</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">12130749</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Schaeffer</surname></string-name>
<etal/></person-group>, <article-title>Rapid sensing of circulating ghrelin by hypothalamic appetite-modifying neurons</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>110</volume>, <fpage>1512</fpage>&#x02013;<lpage>1517</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23297228</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Edwards</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Abizaid</surname></string-name></person-group>, <article-title>Clarifying the ghrelin system&#x02019;s ability to regulate feeding behaviours despite enigmatic spatial separation of the GHSR and its endogenous ligand</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>18</volume>, <fpage>E859</fpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28422060</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C.</given-names>
<surname>M&#x02019;Kadmi</surname></string-name>
<etal/></person-group>, <article-title>Agonism, antagonism, and inverse agonism bias at the ghrelin receptor signaling</article-title>. <source>J. Biol. Chem.</source>
<volume>290</volume>, <fpage>27021</fpage>&#x02013;<lpage>27039</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26363071</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T.</given-names>
<surname>Evron</surname></string-name>
<etal/></person-group>, <article-title>G protein and &#x003b2;-arrestin signaling bias at the ghrelin receptor</article-title>. <source>J. Biol. Chem.</source>
<volume>289</volume>, <fpage>33442</fpage>&#x02013;<lpage>33455</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">25261469</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K.</given-names>
<surname>Toth</surname></string-name>
<etal/></person-group>, <article-title>Encoding the &#x003b2;-arrestin trafficking fate of ghrelin receptor GHSR1a: C-tail-independent molecular determinants in GPCRs</article-title>. <source>ACS Pharmacol. Transl. Sci.</source>
<volume>2</volume>, <fpage>230</fpage>&#x02013;<lpage>246</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">32259059</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K.</given-names>
<surname>Toth</surname></string-name>
<etal/></person-group>, <article-title>Ghrelin receptor antagonism of hyperlocomotion in cocaine-sensitized mice requires &#x003b2;arrestin-2</article-title>. <source>Synapse</source>
<volume>72</volume>, <fpage>e22012</fpage> (<year>2018</year>).</mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>F.</given-names>
<surname>Mende</surname></string-name>
<etal/></person-group>, <article-title>Translating biased signaling in the ghrelin receptor system into differential in&#x000a0;vivo functions</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>115</volume>, <fpage>E10255</fpage>&#x02013;<lpage>E10264</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">30301804</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y.</given-names>
<surname>Chebani</surname></string-name>
<etal/></person-group>, <article-title>Enhanced responsiveness of Ghsr Q343X rats to ghrelin results in enhanced adiposity without increased appetite</article-title>. <source>Sci. Signal.</source>
<volume>9</volume>, <fpage>ra39</fpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27095593</pub-id></mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>W. K.</given-names>
<surname>Kroeze</surname></string-name>
<etal/></person-group>, <article-title>PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome</article-title>. <source>Nat. Struct. Mol. Biol.</source>
<volume>22</volume>, <fpage>362</fpage>&#x02013;<lpage>369</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25895059</pub-id></mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B.</given-names>
<surname>Holst</surname></string-name>, <string-name><given-names>E.</given-names>
<surname>Brandt</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Bach</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Heding</surname></string-name>, <string-name><given-names>T. W.</given-names>
<surname>Schwartz</surname></string-name></person-group>, <article-title>Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling</article-title>. <source>Mol. Endocrinol.</source>
<volume>19</volume>, <fpage>2400</fpage>&#x02013;<lpage>2411</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15905359</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L. M.</given-names>
<surname>Slosky</surname></string-name>
<etal/></person-group>, <article-title>&#x003b2;-Arrestin-biased allosteric modulator of NTSR1 selectively attenuates addictive behaviors</article-title>. <source>Cell</source>
<volume>181</volume>, <fpage>1364</fpage>&#x02013;<lpage>1379.e14</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32470395</pub-id></mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Christopoulos</surname></string-name></person-group>, <article-title>Advances in G protein-coupled receptor allostery: From function to structure</article-title>. <source>Mol. Pharmacol.</source>
<volume>86</volume>, <fpage>463</fpage>&#x02013;<lpage>478</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">25061106</pub-id></mixed-citation></ref><ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L. M.</given-names>
<surname>Slosky</surname></string-name>, <string-name><given-names>M. G.</given-names>
<surname>Caron</surname></string-name>, <string-name><given-names>L. S.</given-names>
<surname>Barak</surname></string-name></person-group>, <article-title>Biased allosteric modulators: New frontiers in GPCR drug discovery</article-title>. <source>Trends Pharmacol. Sci.</source>
<volume>42</volume>, <fpage>283</fpage>&#x02013;<lpage>299</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33581873</pub-id></mixed-citation></ref><ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B. J.</given-names>
<surname>Bender</surname></string-name>
<etal/></person-group>, <article-title>Structural model of ghrelin bound to its G protein-coupled receptor</article-title>. <source>Structure</source>
<volume>27</volume>, <fpage>537</fpage>&#x02013;<lpage>544.e4</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">30686667</pub-id></mixed-citation></ref><ref id="r31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>G.</given-names>
<surname>Ferr&#x000e9;</surname></string-name>
<etal/></person-group>, <article-title>Structure and dynamics of G protein-coupled receptor-bound ghrelin reveal the critical role of the octanoyl chain</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>116</volume>, <fpage>17525</fpage>&#x02013;<lpage>17530</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31416915</pub-id></mixed-citation></ref><ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Inoue</surname></string-name>
<etal/></person-group>, <article-title>Illuminating G-protein-coupling selectivity of GPCRs</article-title>. <source>Cell</source>
<volume>177</volume>, <fpage>1933</fpage>&#x02013;<lpage>1947.e25</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31160049</pub-id></mixed-citation></ref><ref id="r33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R. H. J.</given-names>
<surname>Olsen</surname></string-name>
<etal/></person-group>, <article-title>TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome</article-title>. <source>Nat. Chem. Biol.</source>
<volume>16</volume>, <fpage>841</fpage>&#x02013;<lpage>849</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32367019</pub-id></mixed-citation></ref><ref id="r34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K. G.</given-names>
<surname>Harikumar</surname></string-name>
<etal/></person-group>, <article-title>Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>109</volume>, <fpage>18607</fpage>&#x02013;<lpage>18612</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">23091034</pub-id></mixed-citation></ref><ref id="r35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Saunders</surname></string-name>
<etal/></person-group>, <article-title>Molecular diversity and specializations among the cells of the adult mouse brain</article-title>. <source>Cell</source>
<volume>174</volume>, <fpage>1015</fpage>&#x02013;<lpage>1030.e16</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">30096299</pub-id></mixed-citation></ref><ref id="r36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names>
<surname>Granata</surname></string-name>
<etal/></person-group>, <article-title>Acylated and unacylated ghrelin promote proliferation and inhibit apoptosis of pancreatic beta-cells and human islets: Involvement of 3&#x02032;,5&#x02032;-cyclic adenosine monophosphate/protein kinase A, extracellular signal-regulated kinase 1/2, and phosphatidyl inositol 3-kinase/Akt signaling</article-title>. <source>Endocrinology</source>
<volume>148</volume>, <fpage>512</fpage>&#x02013;<lpage>529</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17068144</pub-id></mixed-citation></ref><ref id="r37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. D.</given-names>
<surname>Violin</surname></string-name>, <string-name><given-names>X. R.</given-names>
<surname>Ren</surname></string-name>, <string-name><given-names>R. J.</given-names>
<surname>Lefkowitz</surname></string-name></person-group>, <article-title>G-protein-coupled receptor kinase specificity for beta-arrestin recruitment to the beta2-adrenergic receptor revealed by fluorescence resonance energy transfer</article-title>. <source>J. Biol. Chem.</source>
<volume>281</volume>, <fpage>20577</fpage>&#x02013;<lpage>20588</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16687412</pub-id></mixed-citation></ref><ref id="r38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. S.</given-names>
<surname>Smith</surname></string-name>
<etal/></person-group>, <article-title>C-X-C motif chemokine receptor 3 splice variants differentially activate beta-arrestins to regulate downstream signaling pathways</article-title>. <source>Mol. Pharmacol.</source>
<volume>92</volume>, <fpage>136</fpage>&#x02013;<lpage>150</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28559424</pub-id></mixed-citation></ref><ref id="r39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L.</given-names>
<surname>M&#x000e9;nard</surname></string-name>
<etal/></person-group>, <article-title>Synergistic regulation of beta2-adrenergic receptor sequestration: Intracellular complement of beta-adrenergic receptor kinase and beta-arrestin determine kinetics of internalization</article-title>. <source>Mol. Pharmacol.</source>
<volume>51</volume>, <fpage>800</fpage>&#x02013;<lpage>808</lpage> (<year>1997</year>).<pub-id pub-id-type="pmid">9145918</pub-id></mixed-citation></ref><ref id="r40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. C.</given-names>
<surname>Snyder</surname></string-name>
<etal/></person-group>, <article-title>Inhibiting clathrin-mediated endocytosis of the leucine-rich G protein-coupled receptor-5 diminishes cell fitness</article-title>. <source>J. Biol. Chem.</source>
<volume>292</volume>, <fpage>7208</fpage>&#x02013;<lpage>7222</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28275053</pub-id></mixed-citation></ref><ref id="r41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. A. J.</given-names>
<surname>Rouault</surname></string-name>
<etal/></person-group>, <article-title>The GPCR accessory protein MRAP2 regulates both biased signaling and constitutive activity of the ghrelin receptor GHSR1a</article-title>. <source>Sci. Signal.</source>
<volume>13</volume>, <fpage>eaax4569</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">31911434</pub-id></mixed-citation></ref><ref id="r42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L. S.</given-names>
<surname>Barak</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Peterson</surname></string-name></person-group>, <article-title>Modeling of bias for the analysis of receptor signaling in biochemical systems</article-title>. <source>Biochemistry</source>
<volume>51</volume>, <fpage>1114</fpage>&#x02013;<lpage>1125</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22221218</pub-id></mixed-citation></ref><ref id="r43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Pantel</surname></string-name>
<etal/></person-group>, <article-title>Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature</article-title>. <source>J. Clin. Invest.</source>
<volume>116</volume>, <fpage>760</fpage>&#x02013;<lpage>768</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16511605</pub-id></mixed-citation></ref><ref id="r44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names>
<surname>Mokrosi&#x00144;ski</surname></string-name>, <string-name><given-names>T. M.</given-names>
<surname>Frimurer</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Sivertsen</surname></string-name>, <string-name><given-names>T. W.</given-names>
<surname>Schwartz</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Holst</surname></string-name></person-group>, <article-title>Modulation of constitutive activity and signaling bias of the ghrelin receptor by conformational constraint in the second extracellular loop</article-title>. <source>J. Biol. Chem.</source>
<volume>287</volume>, <fpage>33488</fpage>&#x02013;<lpage>33502</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22846991</pub-id></mixed-citation></ref><ref id="r45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y.</given-names>
<surname>Shiimura</surname></string-name>
<etal/></person-group>, <article-title>Structure of an antagonist-bound ghrelin receptor reveals possible ghrelin recognition mode</article-title>. <source>Nat. Commun.</source>
<volume>11</volume>, <fpage>4160</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32814772</pub-id></mixed-citation></ref><ref id="r46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B.</given-names>
<surname>Holst</surname></string-name>
<etal/></person-group>, <article-title>Overlapping binding site for the endogenous agonist, small-molecule agonists, and ago-allosteric modulators on the ghrelin receptor</article-title>. <source>Mol. Pharmacol.</source>
<volume>75</volume>, <fpage>44</fpage>&#x02013;<lpage>59</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">18923064</pub-id></mixed-citation></ref><ref id="r47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Wheatley</surname></string-name>
<etal/></person-group>, <article-title>Lifting the lid on GPCRs: The role of extracellular loops</article-title>. <source>Br. J. Pharmacol.</source>
<volume>165</volume>, <fpage>1688</fpage>&#x02013;<lpage>1703</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">21864311</pub-id></mixed-citation></ref><ref id="r48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C.</given-names>
<surname>de Graaf</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Foata</surname></string-name>, <string-name><given-names>O.</given-names>
<surname>Engkvist</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Rognan</surname></string-name></person-group>, <article-title>Molecular modeling of the second extracellular loop of G-protein coupled receptors and its implication on structure-based virtual screening</article-title>. <source>Proteins</source>
<volume>71</volume>, <fpage>599</fpage>&#x02013;<lpage>620</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">17972285</pub-id></mixed-citation></ref><ref id="r49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C. H.</given-names>
<surname>Lee</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Park</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Wu</surname></string-name>, <string-name><given-names>S. G.</given-names>
<surname>Rhee</surname></string-name>, <string-name><given-names>M. I.</given-names>
<surname>Simon</surname></string-name></person-group>, <article-title>Members of the Gq alpha subunit gene family activate phospholipase C beta isozymes</article-title>. <source>J. Biol. Chem.</source>
<volume>267</volume>, <fpage>16044</fpage>&#x02013;<lpage>16047</lpage> (<year>1992</year>).<pub-id pub-id-type="pmid">1322889</pub-id></mixed-citation></ref><ref id="r50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>E. M.</given-names>
<surname>Pfeil</surname></string-name>
<etal/></person-group>, <article-title>Heterotrimeric G protein subunit G&#x003b1;q is a master switch for G&#x003b2;&#x003b3;-mediated calcium mobilization by Gi-coupled GPCRs</article-title>. <source>Mol. Cell</source>
<volume>80</volume>, <fpage>940</fpage>&#x02013;<lpage>954.e6</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">33202251</pub-id></mixed-citation></ref><ref id="r51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B.</given-names>
<surname>Giros</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Jaber</surname></string-name>, <string-name><given-names>S. R.</given-names>
<surname>Jones</surname></string-name>, <string-name><given-names>R. M.</given-names>
<surname>Wightman</surname></string-name>, <string-name><given-names>M. G.</given-names>
<surname>Caron</surname></string-name></person-group>, <article-title>Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter</article-title>. <source>Nature</source>
<volume>379</volume>, <fpage>606</fpage>&#x02013;<lpage>612</lpage> (<year>1996</year>).<pub-id pub-id-type="pmid">8628395</pub-id></mixed-citation></ref><ref id="r52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names>
<surname>Mary</surname></string-name>
<etal/></person-group>, <article-title>Heterodimerization with Its splice variant blocks the ghrelin receptor 1a in a non-signaling conformation: A study with a purified heterodimer assembled into lipid discs</article-title>. <source>J. Biol. Chem.</source>
<volume>288</volume>, <fpage>24656</fpage>&#x02013;<lpage>24665</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23839942</pub-id></mixed-citation></ref><ref id="r53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>De Lean</surname></string-name>, <string-name><given-names>J. M.</given-names>
<surname>Stadel</surname></string-name>, <string-name><given-names>R. J.</given-names>
<surname>Lefkowitz</surname></string-name></person-group>, <article-title>A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor</article-title>. <source>J. Biol. Chem.</source>
<volume>255</volume>, <fpage>7108</fpage>&#x02013;<lpage>7117</lpage> (<year>1980</year>).<pub-id pub-id-type="pmid">6248546</pub-id></mixed-citation></ref><ref id="r54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>V. V.</given-names>
<surname>Gurevich</surname></string-name>, <string-name><given-names>R.</given-names>
<surname>Pals-Rylaarsdam</surname></string-name>, <string-name><given-names>J. L.</given-names>
<surname>Benovic</surname></string-name>, <string-name><given-names>M. M.</given-names>
<surname>Hosey</surname></string-name>, <string-name><given-names>J. J.</given-names>
<surname>Onorato</surname></string-name></person-group>, <article-title>Agonist-receptor-arrestin, an alternative ternary complex with high agonist affinity</article-title>. <source>J. Biol. Chem.</source>
<volume>272</volume>, <fpage>28849</fpage>&#x02013;<lpage>28852</lpage> (<year>1997</year>).<pub-id pub-id-type="pmid">9360951</pub-id></mixed-citation></ref><ref id="r55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. D.</given-names>
<surname>McCorvy</surname></string-name>
<etal/></person-group>, <article-title>Structure-inspired design of &#x003b2;-arrestin-biased ligands for aminergic GPCRs</article-title>. <source>Nat. Chem. Biol.</source>
<volume>14</volume>, <fpage>126</fpage>&#x02013;<lpage>134</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29227473</pub-id></mixed-citation></ref><ref id="r56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names>
<surname>Sanchez-Soto</surname></string-name>
<etal/></person-group>, <article-title>A structural basis for how ligand binding site changes can allosterically regulate GPCR signaling and engender functional selectivity</article-title>. <source>Sci. Signal.</source>
<volume>13</volume>, <fpage>eaaw5885</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32019899</pub-id></mixed-citation></ref><ref id="r57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Bock</surname></string-name>, <string-name><given-names>M.</given-names>
<surname>Bermudez</surname></string-name></person-group>, <article-title>Allosteric coupling and biased agonism in G protein-coupled receptors</article-title>. <source>FEBS J.</source>
<volume>288</volume>, <fpage>2513</fpage>&#x02013;<lpage>2528</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33621418</pub-id></mixed-citation></ref><ref id="r58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.</given-names>
<surname>Wacker</surname></string-name>
<etal/></person-group>, <article-title>Structural features for functional selectivity at serotonin receptors</article-title>. <source>Science</source>
<volume>340</volume>, <fpage>615</fpage>&#x02013;<lpage>619</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23519215</pub-id></mixed-citation></ref><ref id="r59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.</given-names>
<surname>Wacker</surname></string-name>
<etal/></person-group>, <article-title>Crystal structure of an LSD-bound human serotonin receptor</article-title>. <source>Cell</source>
<volume>168</volume>, <fpage>377</fpage>&#x02013;<lpage>389.e12</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28129538</pub-id></mixed-citation></ref><ref id="r60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C.</given-names>
<surname>Valant</surname></string-name>
<etal/></person-group>, <article-title>A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand</article-title>. <source>J. Biol. Chem.</source>
<volume>283</volume>, <fpage>29312</fpage>&#x02013;<lpage>29321</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18723515</pub-id></mixed-citation></ref><ref id="r61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names>
<surname>Bock</surname></string-name>
<etal/></person-group>, <article-title>The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling</article-title>. <source>Nat. Commun.</source>
<volume>3</volume>, <fpage>1044</fpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22948826</pub-id></mixed-citation></ref><ref id="r62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T.</given-names>
<surname>Warne</surname></string-name>, <string-name><given-names>P. C.</given-names>
<surname>Edwards</surname></string-name>, <string-name><given-names>A. G.</given-names>
<surname>Leslie</surname></string-name>, <string-name><given-names>C. G.</given-names>
<surname>Tate</surname></string-name></person-group>, <article-title>Crystal structures of a stabilized &#x003b2;1-adrenoceptor bound to the biased agonists bucindolol and carvedilol</article-title>. <source>Structure</source>
<volume>20</volume>, <fpage>841</fpage>&#x02013;<lpage>849</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22579251</pub-id></mixed-citation></ref><ref id="r63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.</given-names>
<surname>Wootten</surname></string-name>
<etal/></person-group>, <article-title>The extracellular surface of the GLP-1 receptor is a molecular trigger for biased agonism</article-title>. <source>Cell</source>
<volume>165</volume>, <fpage>1632</fpage>&#x02013;<lpage>1643</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27315480</pub-id></mixed-citation></ref><ref id="r64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T.</given-names>
<surname>Kenakin</surname></string-name>, <string-name><given-names>A.</given-names>
<surname>Christopoulos</surname></string-name></person-group>, <article-title>Signalling bias in new drug discovery: Detection, quantification and therapeutic impact</article-title>. <source>Nat. Rev. Drug Discov.</source>
<volume>12</volume>, <fpage>205</fpage>&#x02013;<lpage>216</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23411724</pub-id></mixed-citation></ref><ref id="r65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>N. M.</given-names>
<surname>Urs</surname></string-name>
<etal/></person-group>, <article-title>Distinct cortical and striatal actions of a &#x003b2;-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source>
<volume>113</volume>, <fpage>E8178</fpage>&#x02013;<lpage>E8186</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27911814</pub-id></mixed-citation></ref><ref id="r66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L. S.</given-names>
<surname>Barak</surname></string-name>
<etal/></person-group>, <article-title>ML314: A biased neurotensin receptor ligand for methamphetamine abuse</article-title>. <source>ACS Chem. Biol.</source>
<volume>11</volume>, <fpage>1880</fpage>&#x02013;<lpage>1890</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27119457</pub-id></mixed-citation></ref><ref id="r67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P. J.</given-names>
<surname>Wellman</surname></string-name>, <string-name><given-names>P. S.</given-names>
<surname>Clifford</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Rodriguez</surname></string-name></person-group>, <article-title>Ghrelin and ghrelin receptor modulation of psychostimulant action</article-title>. <source>Front. Neurosci.</source>
<volume>7</volume>, <fpage>171</fpage> (<year>2013</year>).<pub-id pub-id-type="pmid">24093007</pub-id></mixed-citation></ref><ref id="r68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y. M.</given-names>
<surname>Yang</surname></string-name>, <string-name><given-names>D. S.</given-names>
<surname>Kuen</surname></string-name>, <string-name><given-names>Y.</given-names>
<surname>Chung</surname></string-name>, <string-name><given-names>H.</given-names>
<surname>Kurose</surname></string-name>, <string-name><given-names>S. G.</given-names>
<surname>Kim</surname></string-name></person-group>, <article-title>G&#x003b1;<sub>12/13</sub> signaling in metabolic diseases</article-title>. <source>Exp. Mol. Med.</source>
<volume>52</volume>, <fpage>896</fpage>&#x02013;<lpage>910</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32576930</pub-id></mixed-citation></ref><ref id="r69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>N.</given-names>
<surname>Suzuki</surname></string-name>, <string-name><given-names>N.</given-names>
<surname>Hajicek</surname></string-name>, <string-name><given-names>T.</given-names>
<surname>Kozasa</surname></string-name></person-group>, <article-title>Regulation and physiological functions of G12/13-mediated signaling pathways</article-title>. <source>Neurosignals</source>
<volume>17</volume>, <fpage>55</fpage>&#x02013;<lpage>70</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19212140</pub-id></mixed-citation></ref><ref id="r70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T. E.</given-names>
<surname>Robinson</surname></string-name>, <string-name><given-names>B.</given-names>
<surname>Kolb</surname></string-name></person-group>, <article-title>Structural plasticity associated with exposure to drugs of abuse</article-title>. <source>Neuropharmacology</source>
<volume>47</volume> (<issue>Suppl. 1</issue>), <fpage>33</fpage>&#x02013;<lpage>46</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15464124</pub-id></mixed-citation></ref><ref id="r71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names>
<surname>Toda</surname></string-name>, <string-name><given-names>H. W.</given-names>
<surname>Shen</surname></string-name>, <string-name><given-names>J.</given-names>
<surname>Peters</surname></string-name>, <string-name><given-names>S.</given-names>
<surname>Cagle</surname></string-name>, <string-name><given-names>P. W.</given-names>
<surname>Kalivas</surname></string-name></person-group>, <article-title>Cocaine increases actin cycling: Effects in the reinstatement model of drug seeking</article-title>. <source>J. Neurosci.</source>
<volume>26</volume>, <fpage>1579</fpage>&#x02013;<lpage>1587</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16452681</pub-id></mixed-citation></ref><ref id="r72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>N.</given-names>
<surname>Wettschureck</surname></string-name>
<etal/></person-group>, <article-title>Loss of Gq/11 family G proteins in the nervous system causes pituitary somatotroph hypoplasia and dwarfism in mice</article-title>. <source>Mol. Cell. Biol.</source>
<volume>25</volume>, <fpage>1942</fpage>&#x02013;<lpage>1948</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15713647</pub-id></mixed-citation></ref><ref id="r73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T. C.</given-names>
<surname>Yin</surname></string-name>, <string-name><given-names>C. J.</given-names>
<surname>Bauchle</surname></string-name>, <string-name><given-names>A. A. J.</given-names>
<surname>Rouault</surname></string-name>, <string-name><given-names>S. B.</given-names>
<surname>Stephens</surname></string-name>, <string-name><given-names>J. A.</given-names>
<surname>Sebag</surname></string-name></person-group>, <article-title>The insulinostatic effect of ghrelin requires MRAP2 expression in &#x003b4; cells</article-title>. <source>iScience</source>
<volume>23</volume>, <fpage>101216</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32535024</pub-id></mixed-citation></ref><ref id="r74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D.</given-names>
<surname>Lambert</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>Calo</surname></string-name></person-group>, <article-title>Approval of oliceridine (TRV130) for intravenous use in moderate to severe pain in adults</article-title>. <source>Br. J. Anaesth.</source>
<volume>125</volume>, <fpage>e473</fpage>&#x02013;<lpage>e474</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">33070948</pub-id></mixed-citation></ref><ref id="r75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>H. S.</given-names>
<surname>Tan</surname></string-name>, <string-name><given-names>A. S.</given-names>
<surname>Habib</surname></string-name></person-group>, <article-title>Oliceridine: A novel drug for the management of moderate to severe acute pain &#x02013; A review of current evidence</article-title>. <source>J. Pain Res.</source>
<volume>14</volume>, <fpage>969</fpage>&#x02013;<lpage>979</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33889018</pub-id></mixed-citation></ref><ref id="r76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names>
<surname>Pushpakom</surname></string-name>
<etal/></person-group>, <article-title>Drug repurposing: Progress, challenges and recommendations</article-title>. <source>Nat. Rev. Drug Discov.</source>
<volume>18</volume>, <fpage>41</fpage>&#x02013;<lpage>58</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">30310233</pub-id></mixed-citation></ref><ref id="r77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>H. I.</given-names>
<surname>Roessler</surname></string-name>, <string-name><given-names>N. V. A. M.</given-names>
<surname>Knoers</surname></string-name>, <string-name><given-names>M. M.</given-names>
<surname>van Haelst</surname></string-name>, <string-name><given-names>G.</given-names>
<surname>van Haaften</surname></string-name></person-group>, <article-title>Drug repurposing for rare diseases</article-title>. <source>Trends Pharmacol. Sci.</source>
<volume>42</volume>, <fpage>255</fpage>&#x02013;<lpage>267</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33563480</pub-id></mixed-citation></ref><ref id="r78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y. L.</given-names>
<surname>Ng</surname></string-name>, <string-name><given-names>C. K.</given-names>
<surname>Salim</surname></string-name>, <string-name><given-names>J. J. H.</given-names>
<surname>Chu</surname></string-name></person-group>, <article-title>Drug repurposing for COVID-19: Approaches, challenges and promising candidates</article-title>. <source>Pharmacol. Ther.</source>
<volume>228</volume>, <fpage>107930</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34174275</pub-id></mixed-citation></ref><ref id="r79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>E.</given-names>
<surname>Alvarez-Curto</surname></string-name>
<etal/></person-group>, <article-title>Targeted elimination of G proteins and arrestins defines their specific contributions to both intensity and duration of G protein-coupled receptor signaling</article-title>. <source>J. Biol. Chem.</source>
<volume>291</volume>, <fpage>27147</fpage>&#x02013;<lpage>27159</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27852822</pub-id></mixed-citation></ref><ref id="r80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names>
<surname>Pandey</surname></string-name>, <string-name><given-names>D.</given-names>
<surname>Roy</surname></string-name>, <string-name><given-names>A. K.</given-names>
<surname>Shukla</surname></string-name></person-group>, <article-title>Measuring surface expression and endocytosis of GPCRs using whole-cell ELISA</article-title>. <source>Methods Cell Biol.</source>
<volume>149</volume>, <fpage>131</fpage>&#x02013;<lpage>140</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">30616815</pub-id></mixed-citation></ref><ref id="r81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y.</given-names>
<surname>Zhou</surname></string-name>
<etal/></person-group>, <article-title>Design of MC1R selective &#x003b3;-MSH analogues with canonical amino acids leads to potency and pigmentation</article-title>. <source>J. Med. Chem.</source>
<volume>60</volume>, <fpage>9320</fpage>&#x02013;<lpage>9329</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">29094944</pub-id></mixed-citation></ref><ref id="r82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names>
<surname>Mowlazadeh Haghighi</surname></string-name>
<etal/></person-group>, <article-title>Replacement of Arg with Nle and modified D-Phe in the core sequence of MSHs, Ac-His-D-Phe-Arg-Trp-NH<sub>2</sub>, leads to hMC1R selectivity and pigmentation</article-title>. <source>Eur. J. Med. Chem.</source>
<volume>151</volume>, <fpage>815</fpage>&#x02013;<lpage>823</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29679901</pub-id></mixed-citation></ref></ref-list></back></article>
